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ABSTRACT

UNDERSTANDING LIGAND BINDING, SELECTIVITY AND FUNCTIONS ON THE G
PROTEIN-COUPLED RECEPTORS: A MOLECULAR MODELING APPROACH
By Saheem Asghar Zaidi, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Major Director: Dr. Yan Zhang, Ph.D.
Associate Professor, Department of Medicinal Chemistry
Major Director: Dr. Glen E. Kellogg, Ph.D.
Associate Professor, Department of Medicinal Chemistry

The assessment of target protein molecular structure provides a distinct advantage in the rational
drug design process. The increasing number of available G protein-coupled receptor crystal
structures has enabled utilization of a varied number of computational approaches for
understanding the ligand-receptor interactions, ligand selectivity and even receptor response
upon ligand binding.
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The following dissertation examines the results from three different projects with varied

objectives – i) structural modeling of human C-C chemokine receptor type 5 (CCR5) and
assessment of the ligand binding pocket of the receptor, ii) assessment of the selectivity profile
of naltrexone derivatives on the three opioid receptors (µ-opioid, κ-opioid, δ-opioid) with an aim
towards designing selective µ-opioid receptor antagonists, and iii) structural modeling of the
‘active’ state conformation of the κ-opioid receptor in response to agonist binding and
determination of a plausible molecular mechanism involved in activation ‘switch’ of the κ-opioid
receptor.
In absence of a crystal-based molecular structure of CCR5, a homology model of the
receptor was built and the ligand binding pocket was validated. On the basis of evaluation of the
ligand-receptor interactions on the validated binding pocket, structural and chemical
modifications to anibamine, a natural plant product, were proposed to enhance its receptor
binding.
The selectivity of naltrexone (a universal antagonist) was assessed with respect to the
three opioid receptors by employing ligand docking studies and the ‘message-address’ concept.
Multiple address sites were identified on the opioid receptors and structural modifications were
proposed for the naltrexone derivatives for their enhanced selectivity.
In the third project, structural modeling of the active state conformation of the κ-opioid
receptor covalently bound to a salvinorin A derivative (agonist) was attempted via molecular
dynamics simulations. Although the obtained molecular model lacked the signature ‘agonistlike’ conformations, the result provides a template for such studies in the future.
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CHAPTER 1
INTRODUCTION

G protein-coupled receptors (GPCRs) are the large family of proteins expressed on plasma
membrane that function as the receivers of extracellular chemical and physical stimuli. In
seminal studies reported in the late 1960s, Lefkowitz and coworkers demonstrated the first
evidence of biologically active receptors by the exhibition of intracellular reactions in response
to the extracellular binding of hormones tagged with radioactive iodine molecules.1 The group
later isolated the gene encoding for the receptor of the adrenaline hormone and successfully
cloned the β2 adrenergic receptor.2 Around the same time, two groups working independently
published the first complete amino acid sequence of rhodopsin. Results from the previous study
demonstrating the presence of C-terminus of rhodopsin in the cytoplasm and the hydropathic
profiling of the amino acid sequence, taken together, led to the first two-dimensional model of
rhodopsin.3,4 The rhodopsin was imagined as a serpentine originating extracellularly, spanning
the membrane seven times with seven α helical domains, connected by three intracellular and
three extracellular loops, and terminating in the cytoplasm.5 The similarities between the β2
adrenergic receptor and rhodopsin were soon realized, and it was suggested that they might
1

	
  
belong to a family of a larger group of proteins with similar structures but completely different
functions. The family was later termed as the GPCRs, and since then more than 800 genes
coding for GPCRs have been identified. The members of the GPCR family are known to mediate
in a number of physiological functions, including neurotransmission, cardiac function, hormone
responses, inflammation, transmission of infectious diseases, and functions regarding vision,
taste and odor.6
GPCRs are the frequent targets for therapeutic interventions and approximately onefourth of the currently prescribed drugs target GPCRs. Historically, structures for the biologic
ligands are generally identified before the structures of their cognate receptors. Hence, the
computational modeling efforts for the development of GPCR ligands were based on the
‘similarity principle’, according to which structurally similar compounds are likely to possess
similar biological properties.7 The lead compounds for these studies are often identified through
large-scale screenings or are based on the endogenous ligands.
The ligand-based methods have proved to be a great tool in ligand design; however,
molecular structure elucidation of the first GPCR, bovine rhodopsin, was a giant leap forward.
The relatively high quality and detailed structure of inactive ‘dark’ state rhodopsin covalently
bound to 11-cis retinal has paved the way for structure-based drug design.8 This structure
elucidation was followed by solution of several other rhodopsin structures, and for a number of
years rhodopsins were the only available templates for GPCR homology modeling approaches.
The primary reason for this was the abundance of rhodopsin availability from the bovine source
and also because of its higher tolerance to the detergents used for extracting the receptor from its
native lipid bilayer. Furthermore, the distinct mechanism of the rhodopsin activation allowed for
2

	
  
the ability to precisely time its activation by light and to monitor its functional state by
monitoring the spectroscopic properties of retinal.9 Several rhodopsin based homology models
have been used for virtual screening to identify ligands and to study binding of known ligands.
However, these studies had varying success rates because, in spite of sharing many common
structural features with other family A GPCRs, the overall homology is generally less than 25%
and also because of a distinct receptor activation mechanism that lacks activation through a
diffusible ligand.10
The first crystal structures with diffusible ligands to be solved were turkey β1 and human
β2-adrenergic receptors.11,12 Those elucidations required significant innovations in crystallization
techniques including co-crystallization with structured peptides such as antibody fragments or
T4-lyzozyme, and thermostabilizing mutations. The continued efforts have realized several more
GPCR crystal structures including adenosine A2A, dopamine D3, histamine H1, muscarinic M2
and M3, µ-opioid receptor, κ-opioid receptor, δ-opioid receptor, C-X-C chemokine receptor 4, CC chemokine receptor 5, etc.13–17
Although the structural coverage by these crystallized GPCRs is still not complete, it
does provides a much more diverse pool for template selection in homology modeling.
Moreover, these crystallized GPCRs are targets for several ligands. The structure elucidation of
target receptors has provided for detailed ligand-receptor interaction studies with increased
confidence. The insights gained from these analyses, along with the accumulated experience on
ligand-based methods and structure-function relationship studies, promise newer, more potent
and selective ligands.

3

	
  
Recently the crystal structures for the ‘active’ state apoprotein form of rhodopsin, called
opsin, have also been solved, including one in complex with the C-terminal part of transducin G
protein.18 Similarly, crystal structures for β-adrenergic receptors were elucidated in a ternary
complex composed of the receptor, a G protein or a G protein surrogate, and an agonist.19,20
These molecular structures are considered to be the ‘fully active’ conformations of the receptor.
Several other ‘active-like’ structures have also been solved, including adenosine A2A, muscarinic
M2, 5-HT1B and 5-HT2B receptors.21–23 The examination of the inactive and the active forms of
GPCRs has enhanced understanding about the changes in conformational states required for
receptor signaling and has also led to proposed GPCR activation mechanisms. This opens the
door for several computational approaches for studying the receptor response to the ligand
binding, the mechanism of activation of receptor, functional selectivity of the ligands,
understanding basal activity and inverse agonism, etc.
The following sections report structure based approaches aided by the availability GPCR
crystal structures, including homology modeling of a receptor based on a template, ligandreceptor interaction studies on the receptor homology model and on the crystal structures, and
long term receptor-ligand molecular dynamics simulations to understand the receptor activation
mechanism.
Chapter 2 details the structure based drug design strategy in the absence of target protein
crystal structures. Anibamine, a natural plant product, is a C-C chemokine receptor type 5
antagonist and our lab has recently reported its total synthesis.24 The rational design of more
potent anibamine analogs required the understanding of ligand-receptor interactions. Hence,
homology model of the receptor was built, and we propose the ligand binding mode and identify
4

	
  
the interactions involved in the receptor binding. Furthermore, the role of waters in the ligand
binding pocket of CCR5 was explored.
Chapter 3 discusses the modeling approaches for designing selective µ-opioid receptor (MOR)
antagonists based on the ‘message-address’ concept. The lead compounds were synthesized
previously based on the homology models of the opioid receptors. The work presented here,
validates the ‘address’ site conceived in the earlier study and also proposes alternate ‘address’
sites on the receptor.
Chapter 4 details the method and the approach for building ‘active-like’ model of κopioid receptor (KOR) in complex with covalently bound agonist in plasma membrane like
environment. This study was undertaken to discern the mechanism of κ-opioid receptor
activation in response to an agonist.

5
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CHAPTER 2
PREDICTING RECEPTOR-LIGAND INTERACTIONS IN C-C CHEMOKINE RECEPTOR
TYPE 5

2.1 Introduction
The C-C chemokine receptor type 5 (CCR5) belongs to the superfamily of membrane bound G
protein-coupled receptors (GPCRs) and is highly expressed on macrophages and CD4 T cells.
Phylogenetic analysis places CCR5 in the chemokine receptor cluster within the γ-subgroup of
Rhodopsin-type receptors, along with angiotensin/bradykinin related receptors and many orphan
receptors.1,2 Like the majority of the receptors in the cluster, CCR5 is also known interact with
endogenous peptide ligands such as CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL8,
CCL11, CCL14 and CCL16. These ligands are C-C type or β-chemokines, which are
characterized by the presence of two adjacent cysteines near the N-terminus.3 These chemokine
ligands, along with several others, are vital chemoattractants for several mononuclear cell types
to the site of inflammation and to the secondary lymphatic tissues acting via interaction with the
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chemokine receptor. Hence, they play an important role in immune response to foreign antigens,
tissue damage and other physiological insults. The type of mononuclear cell stimulated depends
on the ligand and receptor involved, e.g., C-C chemokines stimulate leucocytes such as
monocytes, lymphocytes and basophils.4 They are also reported to have functions in
angiogenesis, haematopoiesis, embryonic development and metastasis.5 However, CCR5 along
with CXCR4, a closely related chemokine receptor, attracted major attention in late 1990s when
they were reported to be important co-receptors along with CD4 for in vivo HIV-1 portal into
human cells.6
By the early 1990s it was clear that the CD4 expression was a necessary but not sufficient
condition for HIV-1 entry into human cells. This was concluded based primarily on two
observations. Firstly, recombinant CD4 receptor permitted viral entry only when expressed on
human cells. Secondly, viral strains showed distinct tropism. Some viral strains showed efficient
fusion/infectivity on T-lymphocytes, while having poor fusion/infectivity for primary
macrophages. These strains were called T-tropic and were also syncytium-inducing strains.
Other strains were more infective towards macrophages and were termed M-tropic or nonsyncytium inducing strains.7 Viral isolates obtained from recently infected individuals showed
presence of predominantly M-tropic strains; however, an increasing amount of T-topic strains
were seen in later stages of AIDS in many patients.8 Since studies from hybrid cell models
negated the presence of inhibitors, existence of a co-receptor for the HIV-1 virus was postulated.
Unbiased cDNA cloning experiments studying the ability of cDNA library to allow
fusion/infection T-tropic strains on CD4 expressing cells revealed that C-X-C chemokine type 4
(CXCR4) as a co-receptor for T-tropic strains.9 Nonetheless, CXCR4 was still regarded as an
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“orphan” receptor that was termed fusin. In a major breakthrough, study C-C chemokines like
RANTES, MIP-1α and MIP-1β were reported to be important suppressors of M-tropic strains
with little/no effect on T-tropic strains of HIV-1.10 These chemokines were later identified to
bind at CCR5. Within a period of a week in 1996, five independent groups identified CCR5 as a
co-receptor for M-tropic HIV-1 strains by employing both CCR5 ligand-induced loss of function
and recombinant CCR5 induced gain of function studies.11–15 Further definitive evidence came
from the discovery of the mutant CCR5 allele with 32 base pair deletions, termed CCR5 Δ32,
which resulted in a truncated protein at trans-membrane domain 5 that is not expressed at the cell
surface.16–19 Homozygotes of this mutant allele are found with a frequency of ~ 1% among the
North American Caucasian population and this frequency was significantly higher in an exposed
but uninfected population. Further studies revealed that the individuals with such mutant
homozygotes were completely resistant to M-tropic HIV-1 strains, but they remained susceptible
to T-tropic strains.16,17,20–22 Later studies have reported CCR5 to be a crucial co-receptor for viral
transmission and replication during the early and clinically dormant phase of the disease.
Furthermore, CCR5-tropic viruses are reported to be exclusively responsible for more than half
of the HIV-1 infected population, even during late-phase disease, while in the remaining
population HIV-1 also uses CXCR4 as a co-receptor.8
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Figure 2.1. A typical time evolution of HIV-1 tropism indicating viral load (thin line), CD4
count (thick line), CCR5 tropism (grey bar) and CXCR4 tropism (black bar).
Reprint from reference 6.
Another frontier for CCR5 receptor and related chemokines for drug discovery is
developing an effective immunotherapeutic approach for curbing progression of certain
malignancies and cancers.23 Several reports have associated expression levels of chemokines
such as CCL5 and CCL2 with pro-malignant activity of certain cancers.24 CCL5 levels are corelated independently with clinical outcomes in stage II breast cancer, and thus is a diagnostic
marker. Estrogen receptor α (ER-α) expression levels along with CCL5 levels are significant
prognostic indicators in such cases.25 Unregulated expression levels of CCL5 and surface
expression of CCR5 has also been reported in many human prostate adenocarcinoma cells, In
vitro studies on such cell lines have also revealed decreased tumor cell proliferation and invasion
via receptor inhibition by CCR5 antagonists (TAK 779).26 Various mechanisms have been
advanced to explain the pro-cancer activity of CCR5 and related chemokines including
stimulation of cell proliferation activity, pro-angiogenesis functions, increased metastasis and
creation of immunologically privileged sites around cancer cells.23
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Several molecules have been reported to inhibit CCR5 function and they can be classified
into four major classes – small molecules, modified peptides, N-terminal modified ligands (small
molecule attached N-terminally to the peptide) and humanized monoclonal anti-CCR5
antibodies. The majority of small molecule CCR5 antagonists have been identified following
high-throughput screening and subsequent optimization.27 TAK-779 was the first reported small
molecule antagonist. However, it suffered from toxicity and low bioavailability issues. SCH-C
was first CCR5 antagonist to advance to clinical efficacy studies. In this case, the potential
cardiac side effects due prolonging of QTc interval in cardiac cells caused early termination of
the studies. Further optimization of the compound led to vicriviroc that showed greater
selectivity towards the CCR5 receptor over muscarinic and hERG, thus reducing the potential of
cardiac side effects. Aplaviroc was another potential candidate, but its clinical trials were
discontinued because of increased occurrence of idiosyncratic hepatotoxicity. Maraviroc has
been the only successful FDA approved CCR5 targeting drug for HIV-1 infected patients. It
showed better pharmacokinetic and pharmacodynamic profile with sustained reduction in viral
load owing to its prolonged receptor occupancy (t1/2 > 5days).
Anibamine, an alkaloid isolated from Aniba panurensis, was identified as a CCR5
antagonist with micromolar level inhibition of HIV-1 gp120 binding. Anibamine has also been
shown to inhibit prostate cancer cell proliferation, adhesion and invasion. Anibamine provides a
novel structural skeleton that can be further embellished to improve its CCR5 binding and
antagonist activity. Our lab has recently published the total synthesis of anibamine and several
ligands of this class with varying degree of antagonistic activity against CCR5. However,
development of the anibamine analogs required guidance on the probable interactions involved
13
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between the receptor and the ligand. The non-availability of a crystal structure for CCR5
hindered the process. The purpose of this project was to develop a usable CCR5 protein
homology model, including the identification and validation of the small molecule binding
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pocket through computational methods with a goal of helping the development of effective
anibamine cognate ligands.

2.2 Methods and Results
2.2.1 Homology Modeling of CCR5
Homology modeling relies on the similarity between the amino acid sequence of the “target”
protein and an experimentally determined three-dimensional structure of a homologous
“template” protein. At the time of this project, only five types of GPCR crystal structure had
been resolved – bovine rhodopsin28, turkey β2 adrenergic receptor29, human β1 adrenergic
receptor30, human adenosine A2A receptor31 and human CXCR4 chemokine receptor32. The
amino acid sequences of the above receptors along with the target CCR5 protein were retrieved
from the UniProtKB server.33 A PSI-BLAST search (protein-protein BLAST) was performed
with default settings on the amino acid sequences for template identification. Expectedly, the
closely related C-X-C Chemokine receptor type 4 showed highest level of identity (34%) and
similarity (56%). Additionally, cysteine residues responsible for disulfide bonding between
extracellular loop (ECL) 2 and the top of transmembrane helix 3, and between the top of helix 1
and ECL3 were conserved and aligned. The alignment was further refined using CLUSTALX2
with default settings. And the additional modifications were done manually.34 (Figure 2.3)
The small molecule ligand bound crystal structure of C-X-C Chemokine receptor type 4,
retrieved from RCSB database (PDB ID – 3ODU)32, was chosen as the template among other
available CXCR4 structures. The comparative modeling program MODELLER 9v735 was
employed to generate a total of 100 models using the automodel class, where models are built
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while violating minimum restraints obtained from the template protein structure. The best model
was selected on the basis of the inbuilt scoring functions of MODELLER (MOLPDF, DOPE,
GA341), as well as its ability to accommodate the known ligand of CCR5 (maraviroc) inside its
orthosteric ligand-binding site. Ramachandran analysis of the selected model, using the online
server MOLPROBIDITY36, showed 96.9% residues in favored regions and 99.3% residues in
allowed regions, with only two residues outside the allowed region and those were present at a
fairly large distance from the putative ligand binding pocket. (Figure 2.4)

Figure 2.3. Sequence alignment of CCR5 (target) and CXCR4 (template). Disulfide bond
between cysteines shown in yellow dashed lines
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Figure 2.4. A. Representation of best-selected model B. Ramachandran plot of the model

2.2.2 Ligand Sketching
The molecular structures of the ligands (maraviroc, SCHc, TAK779, aplaviroc, vicriviroc and
anibamine) were sketched in Sybyl 8.1, and Gasteiger-Hückel charges were assigned before
energy minimization (10,000 iterations) under the TRIPOS force field (TFF).

2.2.3 Ligand Docking and binding site validation
GOLD 5.1, an automated genetic algorithm based docking program, was used to perform the
docking studies with standard default settings unless specified otherwise.37 The binding site on
the optimized CCR5 receptor model was defined to include all atoms within 10 Å of the
carboxylate carbon atom of Glu283, and a distance constraint of 5 Å was defined between the
quaternary nitrogen atom of the ligands and the carboxylate oxygen of the Glu283 side chain.
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Based on the fitness scores (GOLD score) the best 50 GOLD-docked solutions were selected and
merged onto the receptor model. The interactions between ligand and receptor within the
binding pocket were optimized; clashes and strain energies were removed by energy minimizing
the combined receptor-ligand structures (1000 iterations under Tripos force field). These
optimized models were then subjected to hydropathic analysis with the HINT program.38 The
obtained ligand binding pocket was validated using site directed mutagenesis studies retrieved
from the literature.39 (Table 2.1) The orthosteric site of CXCR4 is more spacious and wider than
most of the other GPCRs crystallized up to that time. This structural characteristic of the
template was also transferred to the CCR5 model. The ligand binding site was effectively made
up of three large hydrophobic sites – the inter-helical region between transmembrane (TM) 3,
TM5 and TM6 at the bottom of the pocket, between TM3 and TM5, and close to TM2. (Figure
2.5)

Figure 2.5. Predominantly hydrophobic ligand binding pocket of CCR5 homology model with
hydrophobic gradient scale, brown (hydrophobic) and blue (hydrophilic).
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Table 2.1. Fold differences of amino acid mutation on inhibition of fusion with viral gp120
(from reference 39)
Location

Mutant

Maraviroc

Aplaviroc

SCH-C

Vicriviroc

TAK779

N-ter

K26A

0.5

6.6

1.5

2.0

1.3

TM1

L33A

0.2

1.7

28

22

32

TM1
TM2

Y37A
Y37F
F79A

1.7
2.5
7.1

0.6
0.4
21

208
0.3
27

395
0.5
192

273
16
8.3

TM2

W86A

83

477

1367

1205

378

TM3

T105A

1.1

8.9

17

2.9

0.4

TM3
TM3

Y108A
Y108F
F109A

207
51
0.6

16
22
2620

60
9.2
1.9

51
46
27

146
111
7.0

TM3

F113A

0.2

8.8

1.3

9.8

0.7

ECL2

K191A

3.4

6.3

8.9

2.0

3.7

TM5

I198A

256

110

75

83

0.6

TM5
TM7

Y251A
Y251F
E283A

69
28
11118

0.2
1.9
1273

0.3
0.2
2077

3.3
0.4
12109

4.4
0.1
5.5

TM7

T284A

5.7

4.2

0.9

0.9

39

i) Maraviroc binding pose
The majority of the docking solutions for maraviroc showed interactions with similar residues.
However, based on the internal ligand conformation, two clusters of docking poses were
obtained. In both of the poses, the isopropyl triazole ring had hydrophobic interactions with
Trp86 and Tyr89 (pocket 1); however, the position of the difloro cyclohexyl and the phenyl ring
switched. In first pose, the cyclohexyl ring resided in the hydrophobic pocket formed by Ile198,
Phe109, Phe112, Trp248 and Phe251 (pocket 2), and the phenyl ring had hydrophobic
19

	
  
interactions with the alkyl part of Lys191 (pocket 3). In this pose the quaternary nitrogen was
involved in interactions with Glu283 and Tyr251. (Figure 2.6A)
As indicated earlier, in the second docking pose of maraviroc the phenyl ring of the
ligand showed interactions with the hydrophobic residues of pocket 2 and the cyclohexyl ring
showed interactions with the hydrophobic residues of pocket 3. This pose also had interactions
between Glu283 and the quaternary nitrogen, a shift in the position of Tyr251 was observed that
allowed hydrogen-bonding interactions between the hydroxyl of Tyr251 and the amide nitrogen
of the ligand. (Figure 2.6B) Overall, both docking poses had general agreement with the sitedirected mutagenesis results.
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Figure 2.6. Docking poses of maraviroc inside CCR5 homology model. A. Pose 1 (Goldscore =
61.04, HINT score = 444) B. Pose 2 (Goldscore = 60.26, HINT score = 431).

ii)Vicriviroc binding pose
Similar to maraviroc two docking poses were also observed for vicriviroc with interactions in
similar regions but with different conformations of the ligand. Residues present in pocket 1 and
21

	
  
pocket 2 were seen to be involved in both the observed docking poses, along with the ionic
interactions between the quaternary nitrogen of the ligand and carboxylate group of Glu283.
(Figure 2.7)

Figure 2.7. Docking poses of vicriviroc inside CCR5 homology model. A. Pose 1 (Goldscore =
58.92, HINT score = 701) B. Pose 2 (Goldscore = 51.70, HINT score = 736).
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iii) Aplaviroc binding pose
Two poses were also observed for aplaviroc inside CCR5 homology model. Interactions,
however, were primarily limited to pocket 2 and pocket 3. Apart from the ionic interactions
between Glu283 and the quaternary nitrogen (observed in both poses), plausible hydrogen
bonding interactions were also observed between the ligand and extracellular loop 2 (for pose 1)
and Asn194 of TM5. (Figure 2.8)

Figure 2.8. Docking poses of aplaviroc inside CCR5 homology model. A. Pose 1 (Goldscore =
49.07, HINT score = 1395) B. Pose 2 (Goldscore = 46.20, HINT score = 698).
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iv) SCH-C binding pose
Pose 1 for SCH-C interactions were observed in pocket 1, 2 and 3, while for pose 2, interactions
were observed in pocket 1 and 2. Interactions with the acidic glutamate residue and quaternary
nitrogen atom of the ligand were observed in both the binding modes. (Figure 2.9)

Figure 2.9. Docking poses of SCH-C inside CCR5 homology model. A. Pose 1 (Goldscore =
59.75, HINT score = 834) B. Pose 2 (Goldscore = 54.10, HINT score = 398).
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v) TAK-779 binding pose
Only one dominant docking pose was observed for TAK779, and the major point of departure
from the binding poses of the other docked ligands was greater than 5 Å distance between
carboxylate group of Glu283 and the quaternary nitrogen, and between the amide nitrogen.
(Figure 2.10) This suggests a limited effect of the Glu283 on TAK-779 binding, which is in
agreement with the site-directed mutagenesis studies. While the effect of glutamate mutation to
alanine at position 283 was remarkably high for other ligands (>2000 to > 12000), its effect on
TAK-779 was limited to 5.5 fold. (Table 2.1)

Figure 2.10. Docking poses of TAK-779 inside CCR5 homology model. Goldscore = 37.13,
HINT score = 919.
The site-directed mutagenesis studies described above validated the binding modes of multiple
ligands following automated docking and minimization of the ligand-receptor complexes. This,
in turn, validates the orthosteric binding site of CCR5 modeled based on the CXCR4 template.
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2.2.4 Docking modes of anibamine
The minimized structure of anibamine was then docked onto the validated homology model
ligand binding pocket of CCR5, employing the same parameters as used for the earlier docked
antagonists. In all the major docking poses the heterocyclic moiety of the anibamine was placed
close to Glu283 due the distance constraint, which allowed interaction between the quaternary
nitrogen of the heterocyclic ring and the carboxylate oxygen of the Glu283 residue. However, the
alkyl moiety adopted a varied number of conformations primarily because the open and spacious
nature of the orthosteric binding pocket does not deter the highly flexible alkyl chain from
exploring different conformations. (Figure 2.11) Analysis of the HINT scores revealed decreased
hydrophobic interactions between the anibamine and the receptor residues. Moreover, high
flexibility of the ligand is likely to result in less frequent and less tight interactions with the
protein surface.
The results indicate that in designing a more active analogue, the anibamine side chains
should be made less flexible, and the possible inclusion of aromatic moieties would also improve
π-π interactions with the aromatic residues lining the CCR5 ligand binding pocket.
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Figure 2.11. Docking poses of anibamine inside CCR5 homology model. A. Pose 1 (Goldscore
= 39.55, HINT score = -448) B. Pose 2 (Goldscore = 35.02, HINT score = -334).
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2.2.5 Generation of water sites inside the homology model
Water molecules can play a very significant role in directing the binding of a small molecule
ligand. The water molecules often form hydrogen bonding bridges between the ligand and the
protein, and thus contribute to the binding enthalpy. Waters, however, can also effect entropic
change in the system. A protein-bound “ordered” water molecule along with the water network
surrounding it may be displaced by an incoming ligand, thereby increasing disorder/entropy of
the system and increasing the binding free energy. The recently elucidated 1.8 Å resolution
crystal structures of the A2A adenosine receptor and the delta opioid receptor indicate the
presence of clusters of water molecules that may play a significant role in defining ligand
binding and selectivity. However as of yet, the high degree of resolution required to resolve
crystal waters has not been possible in the majority of GPCR crystal structures.
To explore the possible contribution of water molecules, a ‘water map’ inside the
homology model of CCR5 was generated using the water Relevance program.40 The water
Relevance relies on two factors - Hydopathic INTeractions (HINT), a non-Newtonian force field
based on experimentally determined logPOctonol/Water, for calculation of interactions; and a Rank
algorithm to assess potential hydrogen bonding ability. The Relevance of waters is then
quantified as a probability score; waters with higher probability are assessed as ‘conserved’ or
tightly bound to the protein and those with lower scores as defined as ‘non-conserved’ or less
tightly bound.40
In theory, a ‘conserved’ water molecule can only be displaced by an atom or group of
atoms that can substitute for all the interactions the outgoing water molecule was involved in. If
the conserved water molecule is present at the solvent accessible surface, it is often surrounded
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by a ‘structured’ shell of water molecules. The displacement of the ‘conserved’ water would also
disrupt the ‘structured’ shell of water molecules surrounding it, and hence provide the binding
event with an entropic impetus. So, designing molecules with such water displacement effects
can have significant improvement in the binding profiles of such ligands.
The water map for the docking site of the homology model was generated using Solvate
feature of HINT/Sybyl 8.1 within 5 Å margin of the docking site and a grid resolution of 1 Å in 2
cycles (2*VDW atom size model, contact distance of 4.0 and VDW bump = 1.10). 29 water
molecules were generated by the search and 29 waters-receptor model complex were then
minimized for 1000 iterations. The 29 generated waters were then checked for degree of
conservation using the water Relevance feature of HINT/Sybyl 8.1. The water molecules with
relevance greater than 0.50 were defined as ‘conserved’. (Figure 2.12) (Table 2.2)

Figure 2.12. Generated water map with 29 waters in the ligand-binding pocket, Red
(Conserved), Yellow (Conserved primarily due to inter-water contacts), Green (non-conserved).
Waters found within 5 Å of docked ligand poses are labeled.
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Table 2.2. Water Relevance scores for the generated waters.
Water
name

Total
HINT
Score

Rank

Wat1

474

Wat2

With CCR5
Relevance

HINT
Score

Rank

3.56

0.86

416

259

5.27

0.92

Wat3

249

2.47

Wat4

600

Wat5

Inter-water

Relevance

HINT
Score

Rank

Relevance

1.39

0.61

59

2.17

0.41

188

2.78

0.64

72

2.48

0.46

0.63

175

1.29

0.42

74

1.18

0.34

2.18

0.80

600

2.18

0.80

0.1

0.00

-0.04

692

3.63

0.93

592

1.33

0.67

100

2.30

0.47

Wat6

242

2.42

0.62

230

2.42

0.62

12

0.00

-0.04

Wat7

362

3.85

0.84

356

2.70

0.72

6

1.15

0.28

Wat8

320

4.12

0.85

349

2.872

0.74

-29

1.25

0.25

Wat9

235

2.37

0.61

235

2.37

0.61

1

0.00

-0.04

Wat10

196

2.39

0.59

57

1.20

0.32

139

1.19

0.38

Wat11

258

3.70

0.79

144

2.39

0.54

114

1.31

0.39

Wat12

352

2.14

0.67

357

2.15

0.67

-5

0.00

-0.04

Wat13

229

3.31

0.73

32

0.00

-0.04

197

3.31

0.73

Wat14

119

2.14

0.47

101

2.14

0.45

18

0.00

-0.04

Wat15

141

5.13

0.80

118

3.83

0.68

23

1.31

0.30

Wat16

5

1.02

0.25

4

1.02

0.26

1

0.00

-0.04

Wat17

192

2.17

0.56

190

1.27

0.41

2

0.91

0.24

Wat18

-91

1.01

0.17

-90

1.01

0.18

-1

0.00

-0.04

Wat19

-83

1.86

0.18

-76

1.86

0.20

-7

0.00

-0.04

Wat20

66

2.00

0.39

75

1.17

0.34

-10

0.84

0.21

Wat21

132

2.07

0.48

-44

0.00

-0.04

176

2.07

0.53

Wat22

183

2.16

0.55

144

2.16

0.51

38

0.00

-0.04

Wat23

123

2.10

0.47

95

2.10

0.44

28

0.00

-0.04

Wat24

221

2.33

0.60

-32

0.00

-0.04

254

2.33

0.62

Wat25

136

2.12

0.49

13

0.00

-0.04

124

2.12

0.48

Wat26

6

0.00

0.04

-21

0.00

-0.04

27

0.00

-0.04

Wat27

19

1.98

0.32

17

1.98

0.33

2

0.00

-0.04

Wat28

125

2.22

0.49

121

1.20

0.38

5

1.02

0.26

Wat29

110

0.99

0.32

-19

0.00

-0.04

128
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To explore the possible roles of waters in ligand binding, the docking modes of the previously
docked ligands were superimposed on the generated water map. Five possible water mediated
interactions scenarios were observed – a) the conserved waters may act as bridge between the
ligand and the protein, b) the conserved waters may get displaced once the ligand binds, c) the
conserved waters may not form a bridge, also need not be displaced, d) the non-conserved waters
may get displaced, e) the non-conserved waters may form a bridge once the ligand binds. (Figure
2.13, 2.14 and 2.15)
Waters 4 and 12 were conserved waters mapped close to Glu283 residue. The sitedirected mutagenesis studies have indicated that Glu283 is critical for binding, and it is
considered to bind to the quaternary amine moiety present in most of the high affinity allosteric
inhibitors of CCR5. Point mutation at this residue results in 1,000 to 10,000- fold decrease in the
fusion inhibition of viral gp120 for most of the ligands, except for TAK779 where the inhibition
drop is less than 10-fold. According to our model, both Waters 4 and 12, or at least one of these,
are displaced during the receptor binding of the ligands. However in the case of TAK779, these
waters may not be displaced, and may act as a bridge. This suggests that binding of the allosteric
inhibitors of CCR5 may be entropy driven due to displacement of the conserved highly ordered
waters molecules along with their associated water network.
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Figure 2.13. First docking mode of maraviroc with superimposed interacting waters. W4 and
W12 (green) conserved but displaced, W2 (brown) conserved and bridges ligand and residues
S179, T177 and Y89, Solvent accounting scores for W2, for protein 246 and for ligand -36.

Figure 2.13. Second docking mode of maraviroc with superimposed interacting waters. W4 and
W12 (green) conserved but displaced, W24 (gray) non-conserved and displaced.

Figure 2.14 Docking mode of TAK779 with superimposed interacting waters. W4 and W10
(brown) conserved and bridges ligand and the protein, W12 (magenta) conserved and close but
not displaced, W18(grey) non-conserved and displaced. Solvent accounting scores for W4, for
protein 489, for ligand -63; W10 for protein 92, for ligand 32; W12 for protein 339, for ligand 92
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2.3 Discussion
The homology model of CCR5 was built using the closely related CXCR4 template. The ligand
binding pocket of the homology model was then validated by analyzing the obtained docking
poses for known the CCR5 antagonists against the site-directed mutagenesis studies available in
the literature. This validation, in turn, also validates the scoring function used in the docking
studies. Anibamine (the lead compound) was docked in the validated docking site of the
homology model. Comparison of binding modes of anibamine with binding modes of other
antagonists suggested that incorporation of constrained hydrophobic moieties to the heterocyclic
skeleton would be beneficial for the receptor binding. Based on this model, second generation of
anibamine analogs with the amine linked aromatic substituents of the heterocyclic skeleton were
synthesized. Third generation of anibamine analogs with further substitutions on the aromatic
substituents are now being tested (the homology model of this chapter has been superseded by
the elucidation of the crystal structure of CCR541). However, the process described here provides
a good template for receptor based design in the absence of protein structure.
Furthermore, the possible roles of the structural water molecules in the binding site were
also explored. Our modeling studies suggest that the remarkable effect of Glu283 on the ligand
binding of CCR5 antagonists could be entropically driven due to the displacement of highly
ordered waters molecules along with disruption of their associated water network. Possible
hydrogen bonding bridges formed by waters were identified for both conserved and nonconserved waters. Although HINT scores for interactions between ligand and the waters were not
high, the presence of potential hydrogen bonding groups cannot be neglected. The potential roles
that waters may play in protein-ligand interactions are often overlooked, particularly for GPCRs.
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We suggest that protein binding pockets can be mapped for water molecules using HINT and the
water Relevance programs, that the generated positions and degree of conservation of water
molecules can help in identifying the possible roles that water, both enthalpic and entropic, may
play in protein-ligand binding.
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CHAPTER 3
MODELING SELECTIVITY OF NALTREXONE DERIVED ANTAGONISTS FOR OPIOID
RECEPTORS

3.1 Introduction
3.1.1 Early research in opioid receptor identification and characterization
Opium is one of the most ancient drugs and its use has been documented in several historical
texts. The word opium comes a Greek word ‘opos’ meaning the juice, in reference to the latex
that leaks out from immature poppy pods when incised. Its use in history has been medicinal for
analgesia and relief in diarrhea, as well as cultural, for example as a euphoriant in rituals.1
Initiation of modern research in the field can be traced back to 1806 when Sertürner first isolated
the active constituent of opium and named it ‘morphine’ after the Greek god of dreams,
Morpheus.2,3 Soon codeine was also isolated and with the advancement in surgical sciences in
the late 1800s morphine and analogs were being used as analgesics and adjuncts to general
anesthetics.1 However, the increased abuse potential of these compounds was soon realized and
efforts were made to develop safer opiates. One such attempt, in 1888, of a drug developed and
marketed as more potent than morphine and with no abuse prospect was heroin.4 Significant
developments have been made since then; however, efforts undertaken to develop compounds
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with reduced abuse potential have met only limited success.
In 1942, nalorphine was synthesized and characterized as the first known opioid
antagonist. It could reverse respiratory depression caused by morphine and precipitate opiate
withdrawal syndrome in opiate addicts, although it did have some analgesic effect too.5,6 This
was followed by development of several other compounds with a wide range of agonist,
antagonist and mixed agonist-antagonist activities.1 A number of animal studies revealed central
nervous system (CNS) as the primary site of action of opiates, and with the advent of radioligand
it was soon realized different ligands had different localization profile inside the CNS.7–9 This
led to a speculation that more than one type of opioid receptors were present in the body and that
these receptors were targets for the endogenous opiates.10
First evidence for such endogenous opiates came from a study where it was found that
that brain extract contains factors that inhibit acetylcholine release in guinea pig ileum and that
this inhibition is reversed by naloxone, an opioid antagonist. These factors were termed
enkephalins and structural characterization revealed these factors to be pentapeptides: Tyr-GlyGly-Phe-Met (Met-enkaphalin) and Tyr-Gly-Gly-Phe-Leu (Leu-enkaphalin).11,12 Soon, other
factors were also identified and grouped in under three major classes - enkaphalin, dynorphin
and β-endorphin.13,14 It is now known that a large majority of these endogenous ligands share the
enkephalin sequence at N-terminus (either Met- or Leu-enkaphalin), and are processed from their
respective precursor peptides. Preproenkaphalin and preprodynorphin yield a large number of
peptides, many of which still remain pharmacologically uncharacterized. For a long time, βendorphins were the only known endogenous opioid ligands that had a different precursor, βlipotropin. However, recently newer peptides have been reported, endomorphin 1 and
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endomorphin 2, whose precursors have not yet been identified, and also do not have
characteristic enkaphalin N-terminus.10
Simultaneous research was also directed towards identification of opioid receptors.
Studies identified a peculiar property of cross-tolerance, where patients tolerant to an opioid
were also tolerant towards a certain group of other opioids and that these could ameliorate drug
withdrawal symptoms of each other. These studies were employed to determine two types of
opioid receptors and were named after the drug used to identify them: µ (morphine) and κ
(ketocyclazocine).15 The third type of receptor was identified in a study where enkaphelins were
found to be more effective than morphine in inhibiting contraction in vas deferens and this effect
was not affected by naloxone treatment. These receptors were termed δ opioid (vas deferens).16
The localization of putative opioid receptors was studied by the shock titration technique
where midbrain central gray and periventricular areas on rhesus monkeys were mapped for
antinociceptive effect of morphine, and whether this nociception was reversed by naloxone.17 In
further studies, analgesia produced by focal electrical stimulation of these regions were partially
reversed by naloxone and other antagonists.18 Biochemical studies indicating sensitivity towards
trypsin and chymotrypsin and insensitivity towards DNase, RNase, neuraminidase and
phospholipase C, suggested the protein nature of the receptor. Further experiments indicating
sensitivity towards detergents and phospholipase A, that releases fatty acids, suggested plasma
membrane bound localization of the receptor.19
A breakthrough came in early 1990s when all three major types of opioid receptors, µ-, κ,
and δ-were cloned. Sequence analysis of these cloned opioid receptors established that they
belong to the super- family of G protein-coupled receptors (GPCR) and the sub-family of
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rhodopsin receptors.20–22 As with any other GPCR, they were found to have seven
transmembrane α-helices connected via three extracellular and three intracellular domains.
Analysis also revealed that these receptors shared about 60% identity, with the highest homology
in the transmembrane region (73–76%) and at the intracellular region (86–100%), while greatest
diversity in amino acid sequence was found at the N-terminus (9–10%), extracellular loop (14–
72%), and the C-termini (14–20%).23

3.1.2 Opioid Receptor Signaling
Early studies on opioid receptor pharmacology had shown that guanine nucleotides such as
guanine triphosphate (GTP) modulate agonist binding. Opioid agonists were shown to stimulate
GTPase activity24 and to inhibit cyclic adenosine monophosphate (cAMP) production.25 Cloning
of the opioid receptors allowed detailed studies in understanding of the molecular mechanism of
receptor dependent signaling pathways. Pertusiss toxin sensitive G-protein, Gαi, was
demonstrated to be involved inhibition of cyclic adenosine mono phosphate (cAMP) production
via opioid receptors.26,27

Classical signal transduction of opioid receptor modulates potassium and calcium ion channels.
After an agonist induces dissociation of Gαi from Gβγ subunit, Gαi interacts with the G-protein
gated inward rectifying potassium channel, Kir3 and deactivates the channel. This leads to
hyperpolarization and inhibition of tonic neural activity.28–30 This positive modulation of
potassium concentration is accompanied by negative modulation of calcium concentration. The
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dissociated Gβγ subunit interacts with P/Q, N or L-type Ca2+ channel, reducing voltage
activation of channel pore opening.31,32 (Figure 3.1)
These receptors are also capable of regulating the secondary messenger pathways.
Agonist induced receptor activation is often concurrent to phosphorylation of the opioid receptor
at C-termini or at intracellular loops where these are at least 15 serine, threonine or tyrosine
residues available for phosphorylation.33 G protein-coupled receptor kinases (GRK) 2/3 are
primary kinases involved in opioid receptor phosphorylation.34,35 Phosphorylation of the opioid
receptor is succeeded by β-arrestin 1/2 recruitment. Surface plasmon resonance (SPR),
glutathione S-transferase pull down and immunecoprecipitation methods have indicated Ctermini of the receptor to be involved in β-arrestin recruitment.36 β-arrestin recruitment is
followed by desensitization, sequestration and internalization of the receptor. This
phosphorylated arrestin bound opioid receptor complex is not entirely inactive, and recruits
alternative signal transduction cascades including mitogen activating protein kinases (MAPKs)
e.g. ERK1/237, c-Jun N-terminal kinase (JNK)38, and p38MAPK39. (Figure 3.1) MAPKs are
known to be involved in cell differentiation, proliferation, apoptosis and transcription factor
regulation. JNK pathway and p38MAPK are involved in inflammatory stress, cytokine activation
and neuropathic pain.36
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Figure 3.1. Summary of the GPCR signaling pathways.
Reprint from reference 33.

3.1.3 µ-opioid receptor (MOR)
MOR is primarily found in the central nervous system either pre- or post-synaptically. Although
MOR is distributed throughout the CNS, high densities are observed in the thalamus, striatum,
interpeduncular complex, medial habenular nucleus, cortex, superior and inferior colliculi, and in
the superficial layers of the spinal cord. MOR is also found in intestinal tracts. MOR is known to
be responsible for supraspinal analgesia, respiratory depression, euphoria, sedation, decreased
gastrointestinal motility, and physical dependence.36 MOR knockout studies have show that the
primary effects of opioids, either beneficial or detrimental, are borne due to stimulation of MOR.
Opioids interacting with MOR are often used for treatment for acute pain, cough, diarrhea and
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acute pulmonary edema.40 However, these opioids are also activate reward pathway and hence
have a huge drug abuse liability. Some MOR agonists are also associated with rapid
development of tolerance. Down regulation of opioid receptor due to sustained exposure to
opioid agonist was suspected to cause drug tolerance.41,42 However, recent evidence suggests
receptor desensitization and internalization due to β-arrestin recruitment may play a major role.
Opioids associated with high tolerance and drug abuse potential, such as morphine, signal
primarily through Gα proteins, while compounds that induce receptor internalization after
arrestin recruitment, e.g. DAMGO, show reduced tolerance.43
Recently, a 2.8Å resolution X-ray crystal structure of Mus musculus MOR in complex
with irreversible morphinan antagonist β-funaltrexamine (βFNA) employing T4-lysozyme fusion
protein strategy was elucidated (PDBID-4DKL).44 The overall architecture of MOR is similar to
other previously crystallized GPCRs with proline related kinks in transmembrane (TM) αhelices. A disulphide bond connects two cysteines and thus links extracellular loop 2 (ECL2) and
the top of transmembrane 3. ECL2 itself forms a hairpin loop. The ligand binding pocket of
MOR, like those of chemokine receptors45, is more solvent exposed than other crystallized
GPCRs, such as β-adrenergic46 and rhodopsin47. The exposed nature of MOR ligand binding
pocket is consistent with relatively shorter dissociation half lives of opioids compared to ligands
interacting with more closed form of binding pockets seen in muscarinic receptor.48 However,
the ligand binding pocket of MOR is deeper much like that of the β-adrenergic receptors,
compared to the shallow pockets in chemokine receptor. Ionic salt bridge ‘lock’ interactions, as
seen in the rhodopsin crystal structure between the conserved DRY (aspartate-arginine-tyrosine)
motif at the intracellular site of TM3 and the acidic residue of TM6 is not observed, because of
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absence of acidic residue at this position. Instead, arginine of the DRY sequence interacts with
the near-by aspartate on the same helix. The DRY aspartate also interacts with a basic arginine at
intracellular loop 2 (ICL2), an interaction that is similar to what is observed in β2-adrenergic
structure; however, in the adrenergic receptor this arginine of ICL2 is replaced by a serine. The
crystal structures observed the formation of dimers tightly associated through TM5 and TM6
(buried surface area 1492 Å2) and to a lesser extant through TM1, TM2 and helix 8 (buried
surface area 615 Å2).44

3.1.4 κ-opioid receptor (KOR)
Kappa receptors are found primarily presynaptically in the limbic and other diencephalic areas,
brain stem, spinal cord, and peripheral tissues. They are responsible for spinal analgesia,
sedation, dyspnea, dependence, dysphoria, and respiratory depression. They are present in brain
regions implicated in reward, cognitive function and stress responses such as ventral tegmental
area, nucleus accumbens, prefrontal cortex, hippocampus, etc. KOR disruption is known to cause
anti-stress effects. This is in agreement with reports correlating elevated levels of dynorphins
under painful and stressful conditions. Thus, the KOR is a good target for conditions such as
anxiety, depression, addiction and other stress induced conditions. The anti-stress effect of KOR
is associated with C-Jun N-terminus (JNK) pathway, however some reports link the effect with
p38MAPK activation.49
The X-ray crystal structure of human KOR was also resolved using T4-lyzozyme fusion
protein with a resolution of 2.9Å and in complex with the KOR selective antagonist JDTic.
(PDBID- 4DJH)50 Not surprisingly, structure of KOR is similar to MOR with slight departures.
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As in the MOR, KOR also lacks an acidic residue at the intracellular region of TM6 to form a
ionic salt bridge interaction with TM3 DRY motif. However, KOR forms a hydrogen-bonding
interaction with a threonine residue present on TM6, possibly stabilizing the antagonist form of
the receptor. Two conformers were seen for ICL2, one with a two turn α-helix and another with
a single turn α-helix. Compared to MOR and DOR, KOR has more acidic residues in the ECL2
region. This acidic entrance to the KOR binding pocket may reflect the basic nature of KOR
selective dynorphins. A parallel and an anti-parallel (probably artifactual) form of receptor
dimers were seen in the KOR crystal structure. The parallel dimer showed association between
TM1, 2 and helix 8 with a buried surface area of 1100Å2.50

3.1.5 δ-Opioid receptor (DOR)
The distribution of DOR is limited to certain regions in CNS including olfactory bulbs, cortex,
striatum and amygdala. DOR is also involved in transmission and integration of painful stimuli,
peripheral nerve endings and regulation of mood.51 Compared to the other opioid receptors, DOR
is a less explored receptor; however, DOR ligands are known to be involved in analgesia,
anxiety, stress and addiction. DOR agonists are reported to increase expression of brain derived
neurotropic factor, a factor also linked with some anti depressants.52 Recent reports have also
indicated suppression of epileptical activity through inhibition of sodium channel.53

The DOR structure is also similar to that of KOR and MOR, as demonstrated by 3.4Å resolution
crystal structure of Mus musculus DOR in complex with naltrindole (4EJ4).54 However, only an
antiparallel form of dimers were observed. Recently a 1.8Å resolution structure of human DOR
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was elucidated employing BRIL fusion protein (4N6H).55 This high-resolution structure revealed
an extensive water network surrounding the co-crystallized ligand (naltrindole) and TM7. More
significantly a sodium site was observed close to the middle of TM2 and TM3. Use of the BRILcomplex attached to the N-terminus instead of the ICL3 incorporated T4-lyzozyme allowed
resolution of ICL3, which adopts a ‘closed structure’ that stabilizes the inactive form of receptor
in absence of an ionic salt bridge.

3.1.6 Importance of MOR selective antagonists
Opioid antagonists have always been vital tools for characterization of opioid agonists. A ligand
is considered as an opioid agonist only if its effects are completely inhibited by an antagonist.
Furthermore, selective opioid antagonists have been employed to understand selectivity profiles
of many agonists.56,57 This is especially important for MOR selective ligands since analgesic,
addictive and other notorious properties of opioid agonists are primarily governed through the
MOR. This is supported by many MOR knockout studies in mice where these effects were
abolished in absence of MORs.58–60 There is an unmet need for a highly selective, nonpeptidyl,
reversible and potent MOR antagonist that may help in understanding structure-functional
relationships, agonist interactions and activation mechanisms of classical and secondary
messenger pathways. However, the utility of a MOR selective antagonist is not limited to the
pharmacological toolkit.
UN’s World Drug Report 2012 estimates global annual prevalence of illegal opiate use to
be between 0.6 to 0.8%. These numbers are even higher in North America where non-medical
use of prescription opioids have aggravated the problem to 3.8 to 4.2% of the adult population.61
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Based on the MOR mechanism, the FDA has approved three drugs – methadone (agonist),
buprenorphine (partial agonist) and naltrexone (antagonist) for treatment of long-term opioid
dependence and addiction.62–64 Methadone and buprenorphine are given as part of morphine
replacement therapy. Methadone, being an agonist, can cause fatal respiratory depression and its
sudden cessation may precipitate withdrawal syndrome. The latter issue has caused abuse of
methadone itself.62,65 A partial agonist, buprenorphine, shows similar side effects, albeit to a
lesser extent.66 The antagonistic action of naltrexone ensures curtailment of issues regarding
respiratory depression and drug abuse liability. However, naltrexone is known to precipitate
opioid withdrawal symptoms and hence decreases treatment adherence rate and beneficial
therapeutic outcomes. Extended release naltrexone formulations have shown some improvement
in this regard.67,68 The use of naltrexone, however, is still limited to patients with end-stage liver
disease and patients requiring chronic pain management.62 Nonetheless, this does provide a proof
of concept for using opioid antagonists for treatment of opiate addiction.
Alcoholism is another major prevalent substance abuse issue. Its been reported that 7 to
8% of Americans are affected by alcohol abuse, which amounts to a loss of about $185 billion in
U.S. health care costs, lost wages, bodily injury, and property damage annually.69 In MOR
knockout mice, where abolishment of opiate effects has been reported earlier, strongly
diminished reinforcement effects of alcohol, cannabinoids and nicotine are seen.70 MOR
silencing is also known to effect maintenance of substance abuse, craving and relapse. Opioid
antagonists, such as naltrexone and naloxone, are reported to curb abuse and treatment of
alcoholism.71–76 However, patients on these antagonists have exhibited increased rates of
suicides, depression and dysphoria.77–79 It is likely that these side effects are caused by the non50

	
  
selective nature of the ligands. Recently, nalfemene, an opioid antagonist was approved for “as
needed” adjunctive treatment of alcoholism by the European Medicines Agency.80 Also, βfunaltrexamine (β-FNA), an irreversible MOR antagonist, is reported to reduce fat intake in fat
preferring mice.81
Several ligands have been developed as potential MOR selective antagonists, including
irreversible antagonists such as β-FNA, clocinnamox and methocinnamox.82 However,
clocinnamox and methocinnamox bind equally well with the three opioid receptors. β-FNA binds
equally well with MOR and KOR, and also shows partial agonism towards KOR.83 Covalent
binding to the receptor of irreversible antagonists also limits their utility in pharmacological
studies. Cyprodime is another extensively studied compound with moderate selectivity and
potency towards MOR.84,85 Conformationally constrained peptides, such as D-Phe-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2 (CTOP) and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP),
are some of the most selective and reversible compounds available.86 However, they suffer from
poor bioavailability and poor distribution across the blood-brain-barrier.87
The ‘Message-Address’88,89 concept has been employed previously to design selective
KOR (e.g norBNI90 and GNTI84) and DOR antagonists (e.g. NTI91). According to this concept a
part of the molecule is essential for activity (message), while additions or modifications can be
made at another site (address) resulting in a changed protein recognition profile of the ligand.
This is possible only if a receptor has a compatible access to the address part of the ligand. Based
on the ‘message-address’ concept and ‘address sites’ identified on the opioid receptor homology
models previously reported by our lab, two potential substitution sites on naltrexone were
identified and a series of ‘addressed’ ligands were synthesized.92,93 The objective of the
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following studies was to model the selectivity profile of those naltrexone derived ligands with
such substitutions.
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3.2 Binding Mode Characterization of 6α- and 6β-N-Heterocyclic Substituted
Naltrexamine Derivatives

3.2.1 Introduction
Naltrexone (NTX) is a universal opioid antagonist with a minimal ‘morphinan’ core and
moderate selectivity towards the MOR. (Figure 2. A number of strategies for embellishing this
core skeleton has provided KOR and DOR selective antagonists.84,90-91 The ‘morphinan’ skeleton
can be regarded as the working part of the molecule that interacts with the receptor and conveys
a ‘message’ for appropriate receptor response. The embellishments help to distinguish between
the receptors and ensure that the ‘message’ is ‘addressed’ accurately. In light of this ‘messageaddress’ concept, a computational research strategy was devised previously in our lab.
Homology models of opioid receptors were built using rhodopsin template and the resulting
homology models were subjected to molecular dynamic (MD) simulations to optimize the
conformation of the model. Naltrexone, a universal opioid antagonist, was then docked unto the
homology models of MOR, KOR and DOR. A comparison of the naltrexone binding pockets
inside the MOR, the KOR and the DOR homology models was made following MD simulations
for optimization of the binding interactions. The protonated amine moiety of naltrexone was
directed towards the conserved acidic aspartate residue inside all the three opioid homology
models; however, contrasts were observed in the region towards which the carbonyl group at the
position C(6) was directed. (Figure 3.4) In the MOR-naltrexone model, the carbonyl group was
directed towards the aromatic residues in extracellular loop 2 (Tyr210 and Phe221) and TM7
(Trp318). In the DOR-naltrexone model, no such aromatic residues were observed in the vicinity
of C(6) carbonyl group. In the KOR-naltrexone model, the aromatic binding locus was seen in
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extracellular loop 2; however in this binding locus only one residue capable of donating
hydrogen for hydrogen bond interactions was observed (Tyr), which is one less than that
observed in the case of MOR-naltrexone model (Tyr and Trp). Therefore, it was postulated that
the region close to the top of TM7 and ECL2 in MOR, inhabited by Trp318 and Tyr210, could
be regarded as a plausible ‘address’ site on the MOR. To this effect, a series of amine-linked
6(C)-substituted naltrexone derivatives were synthesized, with substitutions that can possibly
differentiate between the MOR and the DOR models (incorporation of aromatic group) and
between the MOR and the KOR models (incorporation of a hydrogen bond acceptor in the
aromatic group). To study the effect chirality at the 6(C) position may have, both α and β
configurations were synthesized and studied in vitro radioligand binding assays and [S15]GTPγS
binding functional assays.

Of all the compounds tested NAP and NAQ showed optimal

selectivity and least partial agonism with respect to DAMGO (a MOR selective agonist). (Table
3.1 and 3.2) These compounds also exhibited antinociception activity by blocking the effect of
morphine in mouse tail immersion tests. (Figure 2.5)

N

β-substitution	
  

HO

O
H

α-substitution
Figure 3.3. Naltrexone a univseral opioid antagonist. ‘Morphinan’ skeleton of naltrexone with
arrows indicating two possible steric substitutions at 6(C) postion.
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Figure 3.4. Naltrexone (NTX) docked in the homology models of the MOR, DOR, and KOR.
NTX is in ball and stick, and colored as carbon, red-orange; hydrogen, cyan; oxygen, red and
nitrogen, blue; the amino acid residues are in stick and colored as carbon, grey; oxygen, red and
nitrogen, blue. The receptor homology models are in ribbon. NTX is in A) MOR, red; B) DOR,
cyan; and C) KOR, yellow. Reprint from reference 92.
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The elucidation of opioid crystal structures was a very significant development for this area of
research. In light this advancement, the objective of this project was to characterize binding
modes of 6α- (NAQ) and 6β- (NAP) N-heterocyclic naltrexamine derivatives and to verify the
plausible ‘address’ regions that can guide development of more selective antagonists.

3.2.2 Methods
3.2.2.a Sequence analysis
The amino acid sequences of human opioid and bovine rhodopsin receptors were obtained from
Universal Protein Resource (UniProt)94 (Entry code: P35372 (MOR), P41145 (KOR), P41143
(DOR) and P02699 (Bovine rhodopsin receptor). Sequence alignment analysis was done using
ClustalX 2.095

3.2.2.b Receptor model
The X-ray crystal structures for MOR (4DKL), KOR (4DJH) and DOR (4EJ4) were retrieved
from PDB Data Bank. Sybyl-X 2.0 was used to build each receptor model, hydrogen atoms were
added, Gasteiger-Hückel charges were assigned, and hydrogen coordinates were then optimized
by a 10,0000 iteration minimization while holding all heavy atoms as an aggregate with the
Tripos forcefield (TFF).
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3.2.2.c Ligand Models
Sybyl-X 2.0 was used to sketch the chemical structures of the two lead MOR ligands (NAP and
NAQ) as well as the non-selective ligand NTX, and their Gasteiger-Hückel charges were
assigned before energy minimization (10,000 iterations) with the TFF.

3.2.2.d Ligand Docking
GOLD 5.1, a automated genetic algorithm based docking program was used to perform the
docking studies with standard default settings, unless otherwise specified.96 The binding site was
defined to include all atoms within 10 Å of the γ-carbon atom of Asp3.32 (Ballesteros-Weinstein
numbering, indicating a residue found 18 position towards the amino terminus from the most
conserved residue found in TM3, numbered 50 by convention)97 of the three opioid crystal
structures.

Distance constraints of 4 Å between the piperidine nitrogen of the ligands’

morphinan nucleus and Asp3.32, and between the ligands’ tetrahydrofuran oxygen and the
phenolic oxygen of Tyr3.33 were given, so as to model ionic interaction between the acidic
receptor residue and quaternary nitrogen of the ligand and hydrogen bond interaction between
hydrogen bond donor tyrosine and hydrogen bond acceptor tetrahydrofuran oxygen of the
‘morphinan’ skeleton. Based on the fitness scores and the binding orientation of each ligand
within the binding cavity, the best 50 GOLD-docked solutions were selected and merged into the
receptor.

The interactions between ligand and receptor within the binding pocket were

optimized; clashes and strain energy were removed by energy minimizing the combined
receptor-ligand structures (1000 iterations under TFF). These optimized models were then
subjected to hydropathic analysis with the HINT program. HINT (Hydropathic INTeractions) is
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an empirical free energy scoring tool based on the experimental measurements of logP for 1octanol and water, to estimate atomic level free energies associated with the non-covalent
interactions. 98

3.2.2.e Conformational analysis
Conformational analysis was done in Sybyl-X 2.0 by running a short-term molecular dynamics
simulation. The NAP and NAQ structures were solvated with a water box that was then energy
minimized under conditions described previously (1000 iterations).

A molecular dynamics

simulation on the obtained system was then performed under NVT (constant number of atoms,
volume and temperature at 300K) ensemble for 100 ns with periodic boundary conditions with a
2 fs time-step. The energy-minimized average for the last 10 ns frames of simulation were
analyzed for both the ligands.

3.2.3 Results
3.2.3.a Sequence alignment analyses of three opioid receptors
Analysis of amino acid sequence alignment of all three opioid receptors along with bovine
rhodopsin (Table 3.4 and Figure 3.6) reveals the following:
1) The three human opioid receptors share very high overall homology (over 60% sequence
identity) with higher sequence identity for the putative ligand binding pockets formed
primarily by transmembrane (TM) helices 2, 3, 5 and 6 (putative ‘message’ domain of the
receptor)
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2) An even higher identity (close to 90%) is seen for the intracellular loop (ICL) regions,
which is consistent with the fact that the three opioid receptors share the same family of
G-proteins (Gi/o) for signal transduction, and ICL is the primary region for G-proteins
binding.
3) Much lower sequence identities were observed in the extracellular loop (ECL) regions,
and for both N- and C termini. ECL3 is especially important because it is located directly
above the ‘message’ region of the binding site and carried the lowest sequence identity of
all domains. This further consolidates the argument for a potential ‘address’ domain
defined in the original homology modeling based study.
4) In spite of the high sequence homology in the transmembrane region, two regions of
variations were observed. At ‘site 1’, close to the top of TM6 and TM7, two spots of
deviations were at 6.58 and 7.35 (Ballesteros-Weinstein numbering) positions. (Red
colored numbering in Figure 3.6). At position 6.58, MOR had basic lysine, KOR had
acidic glutamate, and DOR had aromatic tryptophan residue. While at position 7.35,
MOR had aromatic tryptophan, KOR had aromatic tyrosine, and DOR had hydrophobic
leucine residue. This residue was identified as potential address site in the previously
reported homology modeling study. ‘site 2’ was defined by variations observed in regions
close to the top of TM5 (blue colored numbering in Figure 2.6). At position 5.31, MOR
has threonine, KOR has aspartate, and DOR has serine residues. While at position 5.35,
KOR and DOR have acidic aspartate and MOR has a longer by one carbon, glutamate
residue. (Table 3.3)
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Table 3.3. The non-conserved amino acid residue composition of the two binding sites in the
three opioid receptors.
Receptor

Site 1

Site 2

MOR

K3036.58 and W3187.35

E2295.35 and T2255.31

KOR

E2976.58 and Y3127.35

D2235.35 and Y2195.31

DOR

W2846.58 and L3007.35

D2105.35 and S2065.31

Table 3.4. Sequence identity among three opioid receptors.
Percent sequence identity
Domain

Delta/mu

Delta/kappa

Mu/kappa

TM1

69

62

62

TM2

95

86

82

TM3

90

95

100

TM4

43

57

33

TM5

85

77

77

TM6

73

64

73

TM7

78

82

86

EL1

73

67

67

EL2

52

52

30

EL3

21

13

21

IL1

90

90

100

IL2

91

95

91

IL3

86

81

86

N-terminus

28

33

18

C-terminus

40

32

35

Entire protein

62

61

57
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Figure 3.6. Sequence alignment of opioid receptors and bovine rhodopsin. Ballesteros-Weinstein
numbers indicated for the most conserved residues in each trans-membrane (black), important
residues for Site 1 (red), important residues for Site 2 (blue), TM indicated by broad green lines.
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3.2.3.b Conformation analysis
Due to the partial double bond character of the amide linkage of the two compounds (NAP and
NAQ), the ligands can adopt either ‘anti’ or ‘syn’ conformation, as represented for NAP (Figure
3.7A). The averaged conformations measured from the last 10 ns of 100 ns MD simulations
conducted for NAP and NAQ within a periodic water box for both ligands, adopted a
predominantly ‘anti’ conformation, and hence ‘anti’ conformer is expected to be
thermodynamically more stable.
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Figure 3.7. Conformational analysis of NAP inside a water box. A) Representation of “anti” and
“syn” conformations for NAP. B) Conformational analysis results for NAP (magenta) and NAQ
(cyan). Superimposed average structure for last 10 ns of a 100 ns NVT dynamic simulation
inside a water box with PBC. Both NAP and NAQ preferred “anti” conformation over “syn”.
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3.2.3.c Docking studies of the opioid universal antagonist NTX
NTX was used as a ‘probe’ to propose the ‘address’ binding domain within the MOR antagonist
binding pocket in the original homology modeling studies of the three opioid receptors. NTX
also shares a common core with the ligands bound in the crystal structures (β-funaltrexamine in
the MOR, naltrindole in the DOR and JDTic in the KOR), so the conformations of the ligands
co-crystallized with the receptors were used as reference for the docking studies. This modifies
the docking experiment into a simpler issue of placing the 6-position substituents of NTX in the
energetically favorable conformation. In the present study, the CHEM-PLP scoring function of
GOLD program was used since it best replicated the docking solutions of NTX in a fashion
similar to what is observed in each of the co-crystallized ligand within a pocket formed by
helices 3, 6 and 7. The docking of NTX was followed by energy minimization to optimize the
structure models for the ligand receptor complexes. Along with CHEM-PLP scoring function,
which has been optimized for modeling steric complementarity between ligand and protein along
with distance- and angle- dependent hydrogen bonding, the obtained poses were then rescored
with HINT. Optimal docking poses for each NTX-receptor complex were chosen by the highest
CHEM-PLP and HINT scores, which were, in this case, generally in agreement. (Table 3.5)
The residues observed to be involved in primary interactions of naltrexone were highly
conserved among the three opioid receptors (Figure 3.8). Asp3.32 was involved in an ionic
interaction with the 17-position tertiary amino group of the ligand, as constrained during the
docking process. Tyr3.33 formed a hydrogen bond with the furanyl oxygen of the ‘morphinan’
core. The orientation of the 3-phenolic hydroxyl group also matches the orientation seen in MOR
and KOR crystal structures indicating the likelihood of a hydrogen bonding interaction with
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His6.52 through two water molecules. Lys5.39 may be involved in hydrogen bonding interactions
with the 6-position carbonyl oxygen atom and Met3.36, Trp6.48, Ile6.51, Val/Ile6.55, Ile7.39 and
Tyr7.43 formed a hydrophobic pocket to accommodate the morphinan skeleton of the molecule.
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Figure 3.8. Docked poses of naltrexone (orange carbon atoms) inside three opioid receptor
crystal structures: A) MOR B) KOR and C) DOR. Amino acid residue atoms: carbon (cyan),
oxygen (red), nitrogen (blue), sulfur (yellow).
Table 3.5. Fitness scores for each docking modes of NTX, NAP and NAQ
Compounds

Docking
pose

NAQ

KOR

DOR

CHEMPLP

HINT

CHEMPLP

HINT

CHEMPLP

HINT

80

1140

70

1009

85

1035

Site 1

86

1535

57

769

89

1263

Site 2

89

1022

79

489

94

1034

Site 1

81

1345

50

-344

76

465

Site 2

83

1125

56

616

73

-10

NTX
NAP

MOR
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3.2.3.d Analysis of the NAP and NAQ morphinan backbone binding site
All three opioid receptors share a very high degree of sequence similarity in the ‘message’ region
of ligand-binding pocket. So expectedly the morphinan nucleus of NAP and NAQ were both
docked within each receptor in a fashion similar to naltrexone. The ‘message’ component of the
ligands occupied the practically identical ‘message’ domain in the receptors. While the ‘address’
component of the ligands, the amine-linked 6(C) side chain, were primarily clustered around two
different binding loci in the three opioid receptors. Interestingly, the same sites were also
identified in amino acid sequence analysis, where site 1 was located at the top of helix 6 and 7
(including part of ECL3) and site 2 was at the top of helix 5 and ECL2.

3.2.3.e NAP and NAQ in the MOR
As stated earlier the docked poses for NAP in the MOR were clustered around two high scoring
poses related to the two suggested ‘address’ sites. For the first pose NAP adopted a ‘syn’
conformation with respect to the amide linkage. The pyridinyl sidechain of the ligand was
oriented towards site 1 where the side chain could stack with Trp3187.35 with π-π interactions in
addition to a plausible hydrogen bond. (Figure 3.9A) Furthermore, Lys3036.58 may also form a
hydrogen bond with the pyridinyl nitrogen of NAP. For the second pose, the ligand adopted
‘anti’ conformation with respect to its amide linkage where the pyridinyl side chain is placed in a
hydrophobic pocket (Site 2) at the top of helix 5 and near ECL2 (Figure 3.9B). However, lower
HINT scores were observed owing to highly negative interactions due to presence of Glu2295.35
close to the pyridinyl side chain. Thus, it is postulated that NAP prefers site 1 as a ligand binding
pose.
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Figure 3.9. Docked poses of NAP in the mu opioid receptor. A) NAP in MOR binding Site 1.
B) NAP in MOR binding Site 2. NAP atoms: carbon (orange); amino acid residue atoms carbon:
(cyan), oxygen (red), nitrogen (blue).
NAQ follows a similar pattern in its docking solutions. However, for both the major binding
solutions, the ligand adopted the ‘syn’ conformation. As observed in NAP docking mode at site
1, the quinolinyl side chain of NAQ appears to interact with Trp3187.35 with π-π stacking, while
in site 2 (Figure 3.9C), the side chain has an unfavorable interaction with Glu2295.35 (Figure
3.9D). This again suggests Site 1 as a preferred site of interaction for NAQ.
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Figure 3.9. Docked poses of NAQ in the mu opioid receptor. C) NAQ in MOR binding Site 1.
D) NAQ in MOR binding Site 2. NAQ atoms: carbon (orange); amino acid residue atoms
carbon: (cyan), oxygen (red), nitrogen (blue).

3.2.3.f NAP and NAQ in the KOR
Docking of NAP in the KOR also gave two favorable binding poses that were identical to the
results as described earlier for MOR. In both these binding sites for KOR the ligand adopted the
‘anti’ conformation, however GOLD and HINT scoring gave conflicting preference of docking
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modes. (Table 3.3) At site 1 the aromatic side chain may interact with Tyr3127.35 with π-π
interactions, which is similar to the interactions observed in MOR-ligand model. However, the
presence of Glu2976.58 in place of Lys3036.58 of the MOR appears to cause deleterious
interactions with the ligand side chain (as evidenced by lower HINT scores compared to MOR)
(Figure 3.10A). In site 2 of the KOR decreased unfavorable interaction of the NAP side chain is
expected because the presence of one carbon shorter Asp2235.35 residue compared to the
analogous Glu2295.35 of the MOR. (Figure 8B). Moreover, the presence of Tyr2195.31 and
Ser211 (ECL2) may result in more favorable hydrogen bonding interactions with the nitrogen
atom of the side chain. However, according to HINT scores, site 1 was still found to be
preferred, which is in contrast to the preference suggested by CHEM-PLP scores.
NAQ adopted a ‘syn’ conformation in both of its KOR docking poses (Figure 3.10 C, D).
Even more significant hydropathic incompatibility with Site 1 Glu2976.58 is expected for the
larger hydrophobic group (quinolinyl side chain) of NAQ, probably negating the
thermodynamically favorable aromatic π- π stacking interactions of that side chain with
Tyr3127.35. However, the HINT scores for NAQ binding in site 2 (Table 3.3) indicated no
negative interactions with Asp2235.35, also there is a possibility of hydrogen bonding between the
side chain and Tyr2195.31 and/or Ser211 (ECL2). In this case both HINT and CHEM-PLP scores
agreed about the preference of site 2 as a major binding pose for NAQ on KOR.
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Figure 3.10. Docked poses of NAP in the kappa opioid receptor. A) NAP in KOR binding Site
1. B) NAP in KOR binding Site 2. NAP atoms: carbon (orange); amino acid residue atoms
carbon: (cyan), oxygen (red), nitrogen (blue).
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Figure 3.10. Docked poses of NAQ in the kappa opioid receptor. C) NAQ in KOR binding Site
1. D) NAQ in KOR binding Site 2. NAQ atoms: carbon (orange); amino acid residue atoms
carbon: (cyan), oxygen (red), nitrogen (blue).

3.2.3.g NAP and NAQ in the DOR
The docked ligand adopted a ‘syn’ conformation in site 1 of the DOR with the side chain
expectedly stacked in a hydrophobic pocket formed by Trp2846.58 and Leu3007.35 (Figure 3.11A).
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While the pyridinyl side chain was placed in a hydrophobic pocket close to the top of helix 5 and
ECL2 of site 2 in an ‘anti’ conformation. (Figure 3.11B). A preference for the ‘syn’
conformation was observed for NAQ, though it still adopted nearly identical binding poses to
NAP. Notably, these putative interactions seen for DOR-ligand complex failed to replicate any
of the hydrogen bonding interactions observed in the MOR and the KOR models, which offers a
plausible understanding for the lower affinity of NAP and NAQ for the DOR.
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Figure 3.11. Docked poses of NAP and NAQ in the delta opioid receptor. A) NAP in DOR
binding Site 1. B) NAP in DOR binding Site 2. C) NAQ in DOR binding Site 1. D) NAQ in
DOR binding Site 2. NAP and NAQ atoms: carbon (orange); amino acid residue atoms carbon:
(cyan), oxygen (red), nitrogen (blue).
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3.2.3.h Validation of docking mode by site-directed mutagenesis studies
A verification for the binding modes responsible for MOR selectivity of NAP and NAQ was
provided by a site-directed mutagenesis study with a transient Chinese hamster ovary (CHO) cell
line transfected with wild type and mutated MORs. Either Trp3187.35 or Tyr210 in MOR were
mutated to alanine and NTX was used as a control in these studies. (Table 3.6) A dramatic
decrease was seen both in case of NAP and NAQ for mutant W318A, while both bound to the
Y210A mutant with affinities comparable to those of wild type MOR. The binding affinities of
the NTX control were largely unaffected for either mutated receptor compared to their wild
types, agreeing with the unembellished nature of NTX. The preference of the aromatic NAP and
NAQ side chains for π- π stacking and hydrogen bonding interactions with Trp3187.35 of the
MOR in site 1 over Tyr210 (ECL 2) in site 2, as indicated by the docking scores, was also
validated by this site-directed mutagenesis study. Overall, the above observations validated
initial hypothesis that these two leads may recognize a distinct ‘address’ loci in the MOR to
confer their selectivity for the mu over the delta and kappa opioid receptors.
Table 3.6. Binding of ligands to the site-directed mutated MORs.
Compound

Wild type MOR
(nM) ± SEM

Y210A MOR
(nM) ± SEM

W318A MOR
(nM) ± SEM

NTX

IC50
3.90 ± 2.96

Ki
1.85 ± 1.41

IC50
0.95 ± 0.49

Ki
0.45 ± 0.23

IC50
Ki
10.35± 1.64 4.91 ± 0.78

NAP

2.29 ± 0.15

1.09 ± 0.07

1.61± 0.17

0.77 ± 0.08

> 1000

NDa

NAQ

5.42 ± 0.70

2.57 ± 0.33

3.31 ± 1.71

1.57 ± 0.81

> 1000

ND

75

	
  
3.2.4 Conclusions
Comparison of the docking modes of naltrexone on the homology models of MOR, KOR and
DOR, done previously, had indicated a plausible ‘address’ region on the MOR. This address loci
was lined by the residues with aromatic character, along with two hydrogen bond donating
moieties, Trp318 and Tyr210. A series of naltrexone derivatives were synthesized with
substitutions capable of engaging both the aromatic and the hydrogen bond donating character of
the region at 6(C) positions. The two novel naltrexamine derivatives, NAP and NAQ, were
identified as MOR antagonists based on their in vitro and in vivo pharmacological profiles,
which included high binding affinity and selectivity for the MOR over the DOR and KOR.
The docking studies of NAP and NAQ on the crystal structures of opioid receptors
validated the original ‘address’ loci on the MOR albeit with certain alterations. The MOR
address loci still had two hydrogen bond donating moieties; however, instead of aromatic Tyr210
residue the basic Lys303 residue was observed. This alteration is in agreement with the sitedirected mutagenesis studies that showed dramatic loss of binding affinity for NAP and NAQ on
Trp318 mutation but no such effect of mutating Tyr210 residue.
Furthermore, sequence alignment and ligand docking studies also revealed an alternate
‘address’ region on the MOR close to the top of TM5 and ECL2. In this alternate site the MOR
has glutamate residue, while the KOR and the DOR have aspartate residue. The presence of one
carbon longer acidic residue in MOR, can conceivably allow better interactions with the
substituents of naltrexone derivatives. Thus, the ligands with groups interacting at this locus may
show greater discrimination between the opioid receptors.
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The modeling and the site-directed mutagenesis studies showed that NAP and NAQ
preferred site 1, the region lined with the Trp318 and the Lys303 residues in MOR. However,
NAP, NAQ and their cognate ligands may have dual binding modes. The equilibrium between
the two binding modes may shift depending on the nature of substituents attached to the
naltrexamine skeleton.
This model postulates that the hydrogen bond accepting groups on the pyridyl and
isoquinolyl moieties would interact with the basic lysine residue at site 1 on MOR, and hence
provide further selectivity. The ligand binding to site 1 of MOR could also benefit from the
attachment of electron withdrawing groups to the N-heterocyclic aromatic moiety via increase in
cation-π interactions between the N-heterocyclic aromatic group and solvent exposed Lys303.
Furthermore, ligand binding at site 2 could be improved by increasing the linker length
between the morphinan skeleton and the N-heterocyclic moiety that would allow closer
interactions with the glutamate residue at TM5 of MOR.
Based on this model and identification of NAP and NAQ as the lead molecules, a series
of next generation derivatives have been synthesized and pharmacologically characterized. Some
analogs are shown in Table 3.7. For NAP derivatives, addition of the electron donating methyl
group had little improvement in selectivity over NAP. However, increase in the linker length
between the N-heterocyclic aromatic moiety and the morphinan skeleton improved selectivity of
the KOR. For NAQ derivatives, inclusion of the hydrogen bond acceptor nitro group to the
isoquinolyl moiety decreased the MOR binding, probably due to decreased cation-π interactions
between the basic Lys303 side chain and the heteroaromatic ring because of the strong electron
withdrawing nature of the nitro group. In comparison with NAQ, the binding affinity of NCQ
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Table 3.7 Second-generation naltrexamine derivatives. Radioligand binding and selectivity
profile
Name

Cnf

NMP

β

Substituent

CH3

MOR
binding
(Ki)
0.58 ± 0.25

KOR
binding
(Ki)
96.7 ± 12.2

DOR
binding
(Ki)
273.6 ± 1.8

0.73 ± 0.59

203.2 ± 67.0 526.1 ± 78.3

KOR/
MOR

DOR/
MOR

166

472

278

719

N

NGP

β

O
N
H

NNQ

N

α

NO2

5.7±1.7

27.9±2.0

94.7±1.1

4.9

16

0.55±0.01

22.2±2.1

33.9±0.5

40

62

N

NCQ

α

OMe

N
Cl

remained unchanged towards the MOR and the KOR, however the binding improved for DOR,
probably due to increase in the hydrophobic bulk.
The above examples illustrate the difficulty in designing of the selective opioid ligands.
The combination of multiple plausible binding modes and multiple characteristics that a
substitution can impart to the ‘address’ part of the ligand complicates the selectivity profile of a
ligand. However, the modeling studies presented here guided the identification of lead
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compounds selective for MOR. Further application of the “message–address” concept, in
combination with molecular modeling studies, site-directed mutagenesis studies and guided
synthesis, may help in designing more selective ligands for the MOR.
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3.3 Modeling pharmacological profile switch from mu-opioid receptor selectivity to
mu/kappa opioid dual selectivity of 14-position heteroaromatic substituted naltrexone
derivatives

3.3.1 Introduction
Previous docking studies of naltrexone on homology models of MOR, KOR and DOR had
indicated two plausible docking modes and hence two possible sites for addition of
functionalized moieties – the 6th position of morphinan core (described earlier) and the 14
position of morphinan core. Both docking modes had implicated Trp318 and Tyr210 residues as
a plausible ‘address’ site in MOR. (Figure 3.12) As described earlier for 6(C)-substituted
naltrexone derivatives, a series of N-heterocyclic aromatic moieties were synthesized with 14-O
substitution through an ester bond.99,100 (Figure 3.13) Various other groups have reported such
14th substituted naltrexone derivatives with limited selectivity towards MOR, including the
irreversible antagonist clocinnamox.101–104

N

14th	
  position	
  substitution	
  

O
HO

H

O

Figure 3.13. ‘Morphinan’ skeleton of Naltrexone indicating 14th position of substitution
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Figure 3.12. Second binding mode of naltrexone inside MOR homology model.
Reprint from reference 99.
Broadly, 14-O derivatives of naltrexone showed selectivity towards MOR. However, the ester
linkage is susceptible to hydrolysis and so was converted to its isoster amide in second
generation of compounds.105 However, the second generation of 14-substituted naltrexone
derivatives indicated KOR/MOR dual selectivity (Table 3.8 and 3.9). The primary objective of
this project was to model the selectivity profile of 14-O naltrexone derivatives in light of the
newly crystallized opioid receptors, as well as to model subsequent the loss in selectivity for
second generation of 14-N linked derivatives.
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The receptor binding data obtained via radioligand binding studies for first generation (14-O)
and second generation (14-N) of compounds is shown in Table 3.8 and 3.9. The following broad
conclusions can be drawn from the given data –

1. Ester linked 14-substituted compounds were MOR selective, while amine linked
compounds were dual KOR/MOR selective. Loss in selectivity was because of better
binding of the N-linked derivatives to KOR. Binding towards DOR was also improved
for second generation of compounds, especially biphenyl derivatives.

2. Among the O-linked first generation of compounds, the presence of nitrogen in the
aromatic substitution improved binding. No such relationship was seen for the N-linked
second generation derivatives.

3. Changing the linker length in second-generation compounds (third generation
derivatives), which effectively changes the position of the functionalized moiety, does
not have any effect on receptor selectivity.
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Table 3.8. Opioid receptor binding affinity (from radioligand binding assays) and selectivity of
first generation O-linked 14th substituted naltrexone derivatives.
Ki (nM) ± SEM

Selectivity Ratios

MOR (M)

KOR (K)

DOR (D)

K/M

D/M

D/K

NTX

0.20 ± 0.02

5.15 ± 0.26

117.0 ± 8.9

20

450

23

NOP
	
  

0.14 ± 0.03

25.5 ± 6.5

117.4 ± 18.0

182

838

4.6

1.59 ± 0.61

47.8 ± 8.5

170.3 ± 12.6

30

107

3.6

5.58 ± 1.34

49.2 ± 20.4

405.3 ± 234.7

8.8

73

8.2

123.2 ± 38.2

586.4 ±32.4

>10,000.00

4.7

>81

>17

68.4 ± 6.0

>10,000

>10,000

>146

>146

NA

1.44 ± 0.32

67.2 ± 36.7

22.8 ± 19.5

47

16

0.34

2.69 ± 0.72

148.2 ± 55.5

818.4 ± 507.2

55

304

5.5

225.3 ± 46.6

46.6 ± 13.5

907.2 ± 193.0

0.21

4

19

N

N

N

paraNOP

N

N

N
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Table 3.9. Opioid receptor binding affinity (from radioligand binding assays) and selectivity of
second and third generation O-linked 14th substituted naltrexone derivatives.
Ki (nM) ± SEM

NTX
NNP
N

Selectivity Ratios

MOR (M)

KOR (K)

DOR (D)

K/M

D/M

D/K

0.34 ± 0.03

0.90 ± 0.11

95.46 ± 6.09

2.6

281

106

1.51 ± 0.34

0.36 ± 0.01

94.5 ± 6.5

0.24

63

263

0.75 ± 0.28

0.16 ± 0.01

39.9 ± 0.5

0.21

53

249

0.82 ± 0.33

0.33 ± 0.01

10.9 ± 1.3

0.4

13

33

4.34 ± 0.70

0.12 ± 0.001

57.3 ± 4.3

0.03

13

717

3.50 ± 1.87

0.27 ± 0.02

25.1 ± 1.8

0.07

7.2

93

9.09 ± 4.94

0.26 ± 0.01

15.1 ± 0.6

0.03

1.7

58

1.13 ± 0.25

0.13 ± 0.02

1.48 ± 0.05

0.12

1.3

11

6.22 ± 4.01

0.33 ± 0.02

10.5 ± 1.4

0.05

1.7

32

0.29 ± 0.04

0.19 ± 0.03

3.92 ± 0.12

0.66

14

14

0.32 ± 0.04

0.17 ± 0.02

9.1 ± 0.5

0.53

29

29

0.30 ± 0.01

0.14 ± 0.01

0.37 ± 0.04

0.47

1.2

1.2

N

N

paraNNP

N
N

N

N

N
O
N
H

N
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3.3.2 Methods
To understand the loss of selectivity towards the MOR for second generation of compounds, the
most selective first generation compound NOP and its second generation analog NNP were
selected for molecular modeling analysis.

	
  

Figure 3.14. First generation (O-linked) NOP and second generation (N-linked) 14-substituted
naltrexone derivatives.
1. Chemical structures of the ligands were sketched in Sybyl-X 2.0, and their GasteigerHückel charges were assigned before energy minimization (10,000 iterations) with the
TRIPOS force field (TFF).

2. The X-ray crystal structures for MOR (4DKL),44 KOR (4DJH)50 and DOR (4EJ4)54 were
retrieved from PDB Data Bank.

85

	
  
3. Automated docking on these retrieved receptor structures was done utilizing a genetic
algorithm docking program GOLD96 5.1. The binding site was defined to include all
atoms within 10 Å of the γ-carbon atom of Asp3.32 for the three opioid crystal structures
along with a hydrogen bond constraint between the piperidine nitrogen of the ligands’
morphinan nucleus and carboxylate of Asp3.32. The best CHEM-PLP scored solutions
were chosen for further analyses.

4. The ‘morphinan type’ docking pose, as observed in the respective crystal structures, was
seen for both the ligands inside all the three receptors. The conserved residues of TM 3, 6
and 7 formed a hydrophobic pocket lined with Met3.36, Trp6.48 and Tyr7.43. Apart from
a conserved ionic interaction between Asp3.32 and the basic nitrogen of morphinan
skeleton, conserved hydrogen bonding interactions were also seen between Lys5.39 and
6th position carbonyl and Tyr3.33 and tetrahydrofuran oxygen. However the
functionalized ‘address’ moiety i.e. heterocyclic ring also resided in a highly conserved
region close to TM2 lined by Gln2.60.

5. On closer inspection of the receptor binding pockets a variant residue site was observed
one α-helical turn above conserved Gln2.60. In KOR and DOR this position (2.63) is
occupied by Val and Lys, respectively while in MOR Asn occupies the site. A coordinates switch for side-chain terminal nitrogen and oxygen of Asn2.63 of MOR allowed
a plausible hydrogen bonding interaction with the Gln residue present one turn below it.

86

	
  
6. After the ‘switch’ molecular dynamics (MD) simulations were performed in Sybyl-X 2.0
for 10 ps under NVT ensemble. All the residues outside a 15Å sphere radius of 14position carbon of the ligand were defined as aggregates and MD simulations were run
after assigning Gasteiger-Hückel charges and an initial temperature of 300 K. The
average structure of the last 1ps of the simulation was again energy minimized after
assigning Gasteiger-Hückel charges for the 1000 iterations. The above simulation was rerun under same conditions after replacing the ester O atom with an NH group.

3.3.3.Results
Interestingly, conformational changes observed for Gln2.60 of MOR, after the short term
dynamic simulation, allowed for a possible hydrogen-bond interaction with the pyridyl nitrogen
of the ligand. However, this conserved Gln residue among the three receptors was ill directed in
both KOR and DOR (Figure 3.15A). One point of difference in an otherwise very well conserved
docking pocket of the three receptors is at position 2.63, directly above Gln2.60. Based on our
models here, we hypothesize that in MOR Asn2.63, present a helical turn above Gln2.60, helps
to direct Gln2.60 towards the ligand with a greater possibility of hydrogen bonding. However, in
KOR 2.63 this position is occupied by Val and the DOR 2.63 position is occupied by Lys. The
Val of KOR does not have hydrogen bonding groups in its side chains, while Lys was directed
outwards, interacting with the acidic residues present on the ECLs of KOR.
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Figure 3.15A. Superimposed binding mode of NOP (orange balls and stick) in three opioid
receptors: conserved residues (cyan), MOR residues (green), KOR residues (black), and DOR
residues (purple). Pink dashes and green dots represent possible hydrogen-bonding interactions.
Asn2.63 (MOR), but not Val2.63 (KOR) or Lys2.63 (DOR), facilitated the hydrogen-bonding
interaction (green dots) between Gln2.60 and the pyridyl nitrogen atom. The hydrogen-bonding
network yields the high MOR selectivity of NOP over the KOR and DOR.
However, the selectivity of ligands was lost for amide-linked second generation derivatives. To
understand the possible conformational changes in residues around the binding pocket, the ester
‘O’ of the ligand was replaced with an amide ‘NH’ in the same docked pose of ligand. This was
followed by a similar dynamic simulation experiment as described earlier. The resulting model
suggests that, due to a possible internal hydrogen bond between amide NH and pyridyl N, the
pyridyl N of ligand NNP prefers to stay close to the ligand amide. Thus it may be unavailable for
the Gln2.60 linked hydrogen bond, which according to our model described earlier is responsible
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for the selectivity. (Energy calculated for the NNP pose with internal H-bond was 12.5 kcals/mol
lower than the pose without H-bond). Furthermore, the replacement of oxygen of ester, a
hydrogen bond acceptor, with hydrogen bond donor –NH group close to conserved Asp3.32
increments a possibility of another beneficial interaction for all three receptors which results in
the loss of selectivity.

Figure 3.15B. The binding mode of ligand NNP (green balls and stick) in the MOR (cyan).
Conserved hydrogen-bonding interactions, as seen for ligand 2, are shown in pink dashes. A
potential internal hydrogen bond (orange dots) between the amide NH and the pyridyl nitrogen in
ligand 10 disrupts the hydrogen- bonding network, as observed for ligand 2. Furthermore, a
hydrogen-bonding interaction (brown dots) also formed between the amide NH and the
conserved residue Asp3.32 in all three opioid receptors and thus enhanced the binding affinities
of ligand 10 in all three opioid receptors.

89

	
  
Similar dynamics simulation experiments were also run for ligands with N in the 4-position of
the hetroaromatic substitution of the derivatives. In the case of second generation derivatives
(para-NNP), the γ-carbon of the Asp3.32 moved 1.2Å towards the linker, due to a possible
interaction between the acidic Asp residue and the basic –NH linker (Figure 3.15C). A slight
movement was also seen for Tyr7.43, and its hydroxyl was now directed towards the pyridyl ring
(instead of being towards Asp3.32) that may also lead to hydrogen bonding interactions with the
ligand.

Figure 3.15C. Superimposed binding modes of ligand paraNOP (orange balls and sticks) and
paraNNP (green balls and stick) in the MOR (cyan). Interactions, as seen for ligand paraNOP,
are shown in brown dashes. paraNNP and MOR interactions are shown in green dots.
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3.3.4 Conclusions
14-substituted naltrexone derivatives are reported to have discrepant structure-activity
relationships with activity ranging from irreversible antagonism to agonism higher than
morphine even for 17-N-substituted methylcyclopropyl morphinan ligands.102,106-108 14substituted ester linked N-heteroaromatic derivatives of naltrexone synthesized in our lab
showed good selectivity towards MOR. However, this selectivity was lost due to the increased
binding affinity towards both KOR and DOR.
Our model suggests that increased overall binding for all three receptors can be explained
by replacement of the ester oxygen with an amide –NH group, which is capable of forming a
hydrogen bond with the highly conserved acidic Asp3.32 present nearby. In absence of this –NH
group, the ester oxygen interacts adversely with the acidic aspartate. However, presence of
nitrogen in the functionalized substitution can help compensate for this negative interaction in
MOR through hydrogen bonding with glutamate at position 2.60. This also explains importance
of nitrogen in the ring for MOR binding in the first generation of compounds; importance of
nitrogen was also lost in second generation derivatives. Although, the glutamate at position 2.60
is conserved in all three receptors, it is not directed towards the 14-functionalized substitution in
the cases of KOR and DOR. The model indicates that this is because of directive effect of the
non-conserved asparagine residue in MOR, a role that valine (in KOR) and lysine (in DOR) are
unable to fulfill.
The model generated here represents a slight deviation from the ‘message-address’
strategy. Generally, in the application of the ‘message-address’ concept for the development of
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the selective ligands, residues only in the immediate vicinity of the ligand are considered.
However, this model suggests that instead of always relying on the ‘address’ sites composed of
distinct residues for each receptor, other ‘address’ sites can be explored that are formed due to
the conformational state of the conserved residue side chain in response the changed
microenvironment surrounding the conserved residue.
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3.4 Characterization of the selectivity profile of NAQ derivatives
3.4.1 Introduction
As described earlier, NAQ, a C(6)-isoquinoline substitution naltrexone derivative, was designed
to be selective for MOR on the basis of identification of ‘address’ sites in homology models of
opioid receptors. NAQ has been reported to antagonize the effects of full agonist DAMGO (DAla2-MePhe4-Gly(ol)5) in the [35S]GTPγS binding assay and effects of full agonist morphine in
warm-water tail flick immersion assays in mice. NAQ itself shows low efficiency partial
agonism in [35S]GTPγS binding assay.109,92 Moreover, NAQ has shown better efficacy and less
susceptibility to tolerance than naltrexone in reducing high concentration alcohol (30%) intake in
mice.
NAQ’s encouraging results stimulated the need to explore its structure-activity
relationship (SAR) with respect to its selectivity and efficacy. Docking studies, described
previously, postulate two plausible docking modes for NAQ. In the first binding mode, the
‘address’ site on MOR was posited to be near the top of TM6 and TM7 where Trp318 and
Lys318 were modeled to be involved in interactions. While in the second binding mode, Glu229,
close to the top of TM5 and ECL2, can operate as ‘address’ site.110 To facilitate an SAR study,
analogs of NAQ were synthesized based on the above model (as discussed in the section 3.2.4)
and Craig’s plot111 by incorporating substitutions on isoquinoline ring, distance between
isoquinoline ring and epoxymorphinan skeleton, and the aromatic character of C(6) side chain.
These compounds were then evaluated in radioligand binding competition, MOR [35S]GTPγS
binding, and behavioral tail flick immersion assays. NNQ, a 6-nitroisoquinoline analog of NAQ,
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showed antagonistic activity towards MOR for DAMGO (full agonist), along with limited
selectivity towards MOR (MOR ≈ KOR < DOR).

N
OH

O

H
N
H H

O
NO 2
N

OH

Figure 3.16. NNQ, 6-nitro derivative of NAQ

Table 3.10. Opioid receptor binding affinity, selectivity and [35S]GTPγS binding efficacy data
for NNQ and NAP
Selectivity
Compd

Ki (nM)

MOR [35S]GTPγS
Binding

µ

κ

δ

κ/µ

δ/µ

EC50 (nM)

% Emax of
DAMGO

NNQ

5.7 ± 1.7

27.9 ± 2.0

94.7 ± 1.1

4.9

16

31.5 ± 18.7

12.5 ± 1.4

NAQ

0.55 ± 0.15

26.45 ± 5.22

132.50±27.01

48

241

15.83 ± 2.53

The objective of the following project was to model the selectivity profile of NNQ over opioid
receptors. Previously described examples of 14-substituted naltrexone derivatives NOP and NNP
had demonstrated the role of side chain conformations in the binding pocket. To enable more
rigorous sampling of side chain conformation of the protein as well as for the ligand, long-term
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molecular dynamic simulations were performed in ‘plasma membrane-like’ conditions and the
resulting conformations were analyzed.

3.4.2 Methods
1. The molecular structure of the ligand (NNQ) was sketched in SYBYL-X 2.0, and energy
minimization of the structure was performed after assigning Gasteiger–Hückel charges
(10,000 iterations) with the Tripos force field (TFF).

2. The X-ray crystal structures for MOR (4DKL)44, KOR (4DJH)50 and DOR (4EJ4)54 were
retrieved from PDB Data Bank. SYBYL-X 2.0 was also used to prepare the obtained
protein coordinates for ligand docking by extracting the crystallized ligand and the fusion
protein at intracellular loop 3. However, crystallographic waters were preserved. This was
followed by addition of hydrogen atoms and subsequent energy minimization of only the
added hydrogen atoms.

3. GOLD5.296, a genetic algorithm-based automated docking program was employed to dock
the ligand onto these “cleaned” receptor structures. The binding site was defined to include
all atoms within 10 Å of the γ-carbon atom of Asp3.32 for the three opioid crystal structures,
along with a hydrogen bond constraint between the basic nitrogen atom and the carboxylate
group oxygen atoms of Asp3.32. The best CHEM-PLP-scored solutions were chosen for
molecular dynamics (MD) studies.
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4. Gaps in the protein sequence including those due to incorporation of the fusion proteins in
the crystal structure (Leu238-Arg253 in DOR, Leu259-Arg273 in MOR and Ser255Arg263 in KOR) and gaps due to missing electron density in crystal structure of the
receptors (e.g. ECL3 of KOR, Gly300-Ser305) were modeled and refined by MODELLER
9v10.112

5.

Density functional theory (DFT) calculations at the 6-31G* level were employed to
calculate partial atomic charges of the NNQ atoms using NWChem 6.0.113 Force field
parameters and topology files for NNQ were generated utilizing SwissParam.114 The
atomic charges obtained from NWChem were added to the ligand topology file. The
topology and parameter files were further edited, accordingly.

6. Coordinates for the spatial arrangement of the receptors within the lipid bilayer were
retrieved from the Orientations of Proteins in Membranes (OPM) database.115 OPM
estimates arrangement of transmembrane protein inside the lipid bilayer by minimizing the
transfer energy of the protein from water to the lipid membrane.

7. System preparation for MD simulation –
VMD 1.9.1116 was used to prepare the system for MD simulations. Coordinate (pdb) and
connectivity files (psf) were generated for receptor-ligand complex using the psfgen
module. The VMD membrane module was employed to create a lipid bilayer of POPC (1Palmitoyl-2-oleoylphosphatidylcholine). This was followed by addition of 30 Å of water
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layers to both sides of membrane at the vertical axis, using Solvate plugin. All the waters
and POPC molecules at a distance of 0.65 Å or less from the receptor-ligand complex were
then deleted followed by deletion of waters within the POPC membrane. The water system
was then ionized to 0.15 M of NaCl by the Autoionize plugin. (Figure 3.17 representation
of MOR-NNQ-lipid bilayer-ionized water system)

Figure 3.17. MOR(orange cartoon)-NNQ(green balls and stick)-lipid bilayer (cyan lines)aqueous box (blue) representation. 83821 atoms, 66340 bonds, 78042 angles, 85254 dihedrals,
1137 impropers, 17837 residues, 17229 waters, 67 chloride and 49 sodium ions.
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8. Melting Lipids –
All molecular modeling simulations were performed using NAMD 2.8.117 MD
simulations were carried out in four stages. In the first stage, equilibration of the fluidlike lipid bi-layer was performed via minimization (1000 iterations) followed by NPT
equilibration (pressure equilibration) of the lipid tails for a period of 0.5 ns. Simulations
were carried out using the CHARMM118,119 force field with CHARMM22 parameters for
protein, CHARMM27 parameters for lipids and CMAP corrections for proline, glycine
and alanine dipeptides with a time-step of 2 femtoseconds (fs). Periodic boundary
conditions were employed, and Particle Mesh Ewald (PME) summation was used to
calculate long-range electrostatic interactions. Non-bonded interactions were calculated
with a smooth cutoff between 10 to 12 Å with a frequency of 1 fs. Constant pressure and
temperature at 310 K was maintained via Langevin dynamics.

9. Equilibration with constrained receptor-protein complex –
In the second stage, an NPT equilibration of the system was run for a period of 1 ns with
harmonic constraints placed on protein, NNQ and crystallographic water atoms (5
kcal/(mol-Å)) while keeping all the parameters same as earlier.

10. Equilibration with constrained receptor-protein complex –
The harmonic restraint was released in stage 3 and the entire system was equilibrated
using the NVT canonical ensemble for a further 1 ns.
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11. Production Run –
The final production run was conducted using an NVT ensemble where the whole
system was equilibrated for 15 ns.

12. Energy Analysis –
Energy landscape analysis was performed using the NAMD Energy 1.4 plug-in; nonbonded interaction analyses were performed at various distances with a dielectric
constant of 6.5.120 All the atoms, including protein and water molecules within a certain
cutoff distance from the ligand, were included in the energy analyses. The binding modes
with highest non-bonded interactions were selected for further analysis.

3.4.3 Results
Non-bonded interaction energies were calculated for NNQ-receptor complexes at four different
distance cut-offs. (Table 3.11) In general, the choice of distance cut-off didn’t impact nonbonded energy interactions, except at 5 Å for MOR- and KOR- receptor complexes. In the case
of MOR-NNQ complex at 5 Å a decrease in Van der Waals (VDW) was observed, and for KORNNQ complex, a decrease in both Van der Waals (VDW) and electrostatic interactions was
observed, when compared with larger distance cut-offs. For the DOR-NNQ complex the nonbonded interaction values were fairly constant.
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Table 3.11. NNQ–receptor Interaction Energies (kcal/mol).
Radiusa (Å)

MOR−NNQ
Eb

VDWc

Total

KOR−NNQ
Eb

VDWc

DOR−NNQ
Total

Eb

VDWc

Total

10

–13.76 –71.64 –85.40 –22.52 –66.35 –88.87

–8.37

–63.49 –71.86

8

–14.69 –69.89 –84.58 –21.43 –66.04 –87.47

–8.18

–63.24 –71.42

6

–17.44 –67.83 –85.27 –23.00 –62.90 –85.90

–6.71

–63.82 –70.53

5

–16.45 –63.89 –80.34 –19.27 –58.52 –77.79 –11.70 –60.49 –72.19

a

Distance from the docked ligand NNQ; bE: Electrostatic interaction; cVDW: Van der Waals’
interaction.

3.4.3.a Binding mode of NNQ in MOR
In the best scored non-bonded interaction pose for the NNQ-MOR complex the morphinan
skeleton of the molecule agreed with the binding pose of the crystallographic ligand. (Figure
3.18) The morphinan core resided inside a hydrophobic pocket lined by Met3.36, Trp6.48, Ile7.39
and Tyr7.43. The His6.52 conformation showed a plausible of hydrogen bond interaction with the
phenoxy oxygen through a water molecule. Asp3.32 was involved in interactions with both the
protonated nitrogen of the core and the 14-position hydroxyl. The amide linker also formed a
hydrogen bond with backbone carbonyl of Ile6.51 through a water molecule. The nitroisoquinoline group of the functionalized moiety was placed towards TM5, where its nitro group
may form a water-mediated hydrogen bonding network with Glu5.35. Notably, position 5.35 was
one of the sites identified (site 2) as an alternative ‘address’ site for NAP and NAQ.
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Figure 3.18. NNQ in green balls and sticks, interacting MOR residues in sticks (with both
residue and Ballesteros–Weinstein indices), ionic interaction including hydrogen bonding
interactions shown with black broken lines.

3.4.3.b Binding mode of NNQ in KOR
The morphinan docking pose inside KOR was similar to that observed in MOR. Met3.36,
Trp6.48, Leu3.29 and Tyr7.43 formed a hydrophobic pocket surrounding the core skeleton.
Asp3.32 also exhibited similar interactions with protonated amine and the 14-position hydroxyl,
and His6.52 formed a hydrogen bonding network around the phenoxy oxygen through water
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molecules. However, placement of the nitroisoquinoline moiety showed variation, instead of
residing close to TM5, the functionalized moiety was placed between TM2, 3 and 7. The nitro
group is involved in an interaction between backbone Ser210 (ECL2) and Gln2.60. This binding
mode was different than ‘address’ sites identified earlier as ‘site 1’ and ‘site 2’.

Figure 3.19. NNQ in green balls and sticks, interacting KOR residues in sticks (with both
residue and Ballesteros–Weinstein indices), ionic interaction including hydrogen bonding
interactions shown with black broken lines.
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3.4.3.c Binding mode of NNQ in DOR
Although similar residues were involved in forming hydrophobic linings around the morphinan
skeleton, there was an overall displacement of the core, with the nitroisoquinoline substituent
directed towards TM7. In this binding mode, the nitro group can form interaction with the ECL3
arginine and TM7 His7.36. Due to displacement of the morphinan skeleton, the conserved acidic
Asp3.32 was now directed away from the protonated nitrogen. Hence, only one interaction
(between Asp and 14-hydroxyl) is plausible, as evidenced by low electrostatic energy for DOR
complexes.

Comparison between binding modes of NNQ on MOR, KOR and DOR
In MOR-NNQ complex the functionalized nitroisoquinoline moiety occupies the ‘address’
region identified as ‘Site 2’, where it forms hydrogen bonding interactions with Glu5.35 through
waters. This glutamate residue is a non-conserved residue among the opioid receptors. In the
KOR and the DOR this residue is replaced by one carbon shorter acidic residue, aspartate.
According to the binding models generated here, interactions through water bridges may not be
possible for DOR and KOR. Hence, NNQ adopts a different binding mode in the DOR and the
KOR. In KOR, loss of ‘site 2’ interactions is compensated by interactions at TM7 and ECL2.
However, in DOR it is also accompanied by loss of ionic bridge interactions between the
protonated amine and the conserved aspartate.
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Figure 3.20. NNQ in green balls and sticks, interacting DOR residues in sticks (with both
residue and Ballesteros–Weinstein indices), ionic interaction including hydrogen bonding
interactions shown with black broken lines.

3.4.4 Conclusions
When compared to NAQ, NNQ shows a 10-fold decrease in selectivity towards MOR over KOR,
and a 15-fold decrease in selectivity towards MOR over DOR. This decrease in selectivity is
primarily due to the 10-fold loss of binding affinity of NNQ to MOR. According to the model
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discussed earlier in the section 3.2.4, inclusion of the nitro group on the heteroaromatic
substituent can have a dual effect on the MOR binding. The nitro group can act as a hydrogen
bond acceptor towards the lysine residue at position 6.58 of site 1 in MOR. However, the cationπ interactions are expected to decrease due to the strong electron withdrawing character of the
nitro group. The docking followed by a 15 ns equilibration study presented here indicates that the
NNQ prefers site 2 ‘address’ instead. The interactions between the acidic glutamate residue at
position 5.35 and the nitro group are mediated through water molecules.
The nitro group on the heteroaromatic substitution, according the previous model, is
expected to decrease the KOR-NNQ binding due to the presence of an acidic glutamate residue
at position 6.58 of site 1 in KOR. Possibly, the presence of aspartate instead of glutamate at
position 5.35 in KOR hampers the interactions seen for the MOR at site 2 through a single water
molecule bridge. However, the nitro isoquiniline substitution locates another ‘address’ region,
the region identified earlier for the 14-substituted naltrexone derivatives where the nitro group
interacts with the conserved glutamine residue at position 2.60 and with the Ser210 of the ECL2.
There is only a slight increase in DOR binding for NNQ with respect to NAQ, even after
the addition of two new plausible interactions of the nitro group with hydrogen bond donors at
helix 7 and ECL3. This may be because of dislocation of the ‘morphinan’ nucleus resulting in
decreased interactions with the conserved acidic residue at position 3.32.
These results underline the possibility of multiple address regions in a receptor that a
ligand can avail. A ligand itself can also have multiple binding modes and the equilibrium
between those binding modes is a function of characteristics a substitution imparts to the ligand.
The study also indicates the importance of including water molecules in modeling the selectivity
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of opioid ligands. The tightly held water molecules on the surface of the protein may add
exploitable features on the ‘address’ region of the receptor. So it may be advisable to incorporate
dual functionalized substituent moieties to design further selective compounds.
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3.5 Discussion
The development of MOR selective antagonists requires identification of distinct address sites on
the MOR. Following the identification of the address loci on the receptor, suitable substitutions
can be made on the universal antagonists that may help in discriminating among the opioid
receptors. One such address loci was identified based on the homology models of the opioid
receptors. The docking studies of the universal antagonist, naltrexone, suggested two plausible
positions for substitutions to exploit the identified address loci in MOR – 6(C) and 14(C) of the
naltrexone.
The docking studies on 6-position substituted naltrexone derivatives validated the address
loci identified in the homology model. Furthermore, an alternate ‘address’ locus was identified
by sequence alignment and docking studies on the 6-position substituted derivatives. The model
suggested the presence of two address regions in the opioid receptors and the ligand could adopt
conformations that allow interactions with either of the address loci.
The docking studies on 14-position substituted naltrexone derivatives indicated presence
of a third address region, formed due to the conformation adopted by an otherwise conserved
residue side chain.
The long term MD simulation studies of second generation NNQ, a 6(C)-substituted
naltrexone derivative, inside the opioid receptors embedded in the lipid bilayer iterated the
importance of address loci identified previously. However, the nature of the interactions between
the address loci on the receptor and the substituents was different from the interactions conceived
in the previous model, especially due to incorporation of water molecules in the model.
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Furthermore, a functionalized moiety also improved the binding of NNQ to KOR and DOR via
interactions to the regions identified earlier and the new regions respectively.
The ability of ligands to adopt different conformations and the presence of multiple
‘address’ sites on the opioid receptors complicates the directed design of selective opioid ligands
based on the ‘message-address’ concept. The presence of multiple address sites suggests that
more selective ligands can be developed with multiple functionalized moieties that may interact
with more than one address region in one conformation or restrict the binding mode of the ligand
to a single conformation.
Overall, the work presented here represents the progression of ligand-receptor
interaction models from a simple homology modeling based model to a lipid embedded-crystal
structure based model. Continued application of the ‘message-address’ concept based on
identification of address site interactions can help in guided synthesis of MOR selective
antagonists.
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CHAPTER 4
UNDERSTANDING OPIOID RECEPTOR ACTIVATION MECHANISM THROUGH
MOLECULAR DYNAMICS SIMULATIONS

4.1 Introduction
4.1.1 GPCR conformational diversity and crystallized GPCR agonist complexes
The canonical ternary complex model of GPCR signaling suggests a unidirectional response of
the agonist-activated receptor through heterotrimeric G proteins. However, it is now accepted
that upon binding of endogenous or synthetic agonists a receptor exhibits a far more complex
signaling and regulatory profile. During the receptor activation, conformational changes in the
transmembrane and cytosolic parts of the receptor provide an interaction surface for the
incoming G protein. Most GPCRs also provide specific signaling through localized
conformational changes at the carboxy terminus via interactions with various factors present
close to the plasma membrane. Recently, signaling through intracellular compartments such as
endosomes has also been reported.1 Many GPCRs also exhibit basal (i.e. constitutive) activity,
and agonists are known to modulate this activity by increasing (full agonist), partially increasing
(partial agonist) or decreasing (inverse agonist) the G protein coupling response. The exact
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molecular mechanisms involved in the receptor response upon ligand binding remains to be
elucidated; however, recent advances in structural biology, particularly in the field of meso
crystallization, have provided significant insights.
In some of the pioneering studies of the late 1990s, before determination of first the
GPCR crystal structure, the importance of TM movement for receptor signaling was revealed.
Sheikh and co-workers engineered a metal binding site close to the cytosolic part of TM3 and
TM6 by mutating wild type residues to histidine in rhodopsin and β2 adrenergic receptors (βAR).2,3 The mutant receptors were able to stimulate G protein binding in response to an agonist.
However, this ability was lost in the presence of metal ions, indicating that the cytosolic part of
TM3 and TM6 lie in close proximity and a change in their conformational orientation is likely to
be involved in receptor activation. Structural confirmation of the proximity of TM3 and TM6
came from the resolution of the first X-ray crystal structure of rhodopsin in the inactive ‘dark’
state in complex with covalently bound 11-cis retinal. In this structure, Arg3.50 of TM3 forms
ionic interactions with Tyr6.30 of TM6, which was later named as ‘ionic lock’ that preserves the
receptor in the inactive state.4 Twenty four more structures of rhodopsin have been crystallized
since, which represents about one-third of all the crystallized GPCRs available in the Protein
Data Bank (PDB).5
A large majority of rhodopsins crystallized are of bovine origin (21) and represent
multiple states of receptor activity – ‘dark’ state (10), bathorhodopsin (1), lumirhodopsin (1),
deprotonated intermediate (1), and meta II rhodopsin/meta rhodopsin III (8). Only low resolution
electron density maps of meta I rhodopsin intermediate are available. All of the intermediate and
active forms of rhodopsin are either photo-activated or were crystallized while soaked in the all121

	
  
trans active form of retinal and intermediates were stabilized by adjusting temperature or the
pH.5
The availability of experimentally determined atomic coordinates for rhodopsin in
multiple receptor conformations has delivered insights into the structural changes associated with
receptor activation. With respect to the ‘dark’ state, only local rearrangements in retinal binding
site are seen in intermediate states. While transiting from lumirhodopsin to meta I rhodopsin,
small scale changes were observed that include a slight rotation of TM6 and movement of TM5
away from TM3.6,7 However, compared to the inactive form large scale deviations were
observed in the activated form of the receptor, in both photo-activated and all-trans cocrystallized structures regardless of the presence or absence of interacting C-terminus residues of
transducin (G protein cognate of rhodopsin).8–10 In the activated opsin form TM6 is tilted
outwards by 6-10 Å due to rotation and not due to hinge movement, while TM5 extends a few
turns into the intracellular region and also moves 2-3 Å closer to TM6. In the extracellular part,
an opening is created between TM5 and TM6, and between TM1 and TM7, and displacement of
ECL2 is observed that probably allows retinal to escape from the receptor following hydrolysis
of the covalent linkage. Rearrangements in the conserved E(D)RY sequence of TM3 and
NPxx(Y)F of TM7 are also observed. The ‘ionic lock’ between Glu2476.30 and Thr2516.34, and
Arg1353.50 of the DRY sequence is broken. Tyr2235.68 moves towards inter-helical region to
stabilize Arg1353.50, which in turn also interacts with the C-terminus of transducin.9,10 Increased
localized bends at TM2 due to Gly892.56 and Gly902.57 are observed in batho- and lumirhodopsin
structures; however, they again relax in meta II structures.5
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Although the resolution of the crystal structures is limited, electron density reflecting water
networks were observed indicating regional constraints binding the waters. In the inactive state
of rhodopsin, the interconnected water network begins at Trp2656.48, Asp832.50, Ser2987.45 and
Asn3027.49 (of NPxxY domain), and ends at a ‘hydrophobic barrier’ formed due to leucine and
methionine residues of TM1, TM2, TM3 and TM6. The water-mediated link between Trp2656.48
and Ser2987.45 is broken in the active state. However, Ser2987.45, Asn551.50, Asp832.50, and
Asn3027.49 continue to stabilize Pro3037.50 kink. Rotation of the TM6 opens up a ‘hydrophobic
barrier’, allowing Tyr2235.58 and Tyr3067.53 into the inter-helical region. These residues form an
extensive hydrogen bond network through waters linking the DRY motif of TM3 and helix 8,
which in turn also interacts with transducin. Thus, rotation of Trp2656.48 and movement of TM6
results in a water network connecting residues close to the ligand binding pocket and residues
interacting with transducin.10
Perhaps the most studied GPCR in terms of receptor activation is β2-adrenergic receptor
(β2-AR), which also serves as the prototypical aminergic receptor. Crystallization of the β2-AR
was made possible by two differing approaches for the same problem of conformational
instability of ICL3. In the first approach, the receptor was crystalized in complex with a Fab
antibody that recognizes ICL3 residues as epitopes. In the second strategy, the ICL3 loop was
replaced by a well-structured T4-lyzozyme subunit.11 By employing the T4L-fusion method,
crystal structures for agonist-bound β2-ARs were elucidated in complex with the GS protein
substitute nanobody (Nb80)12 and with nucleotide-free GS protein13. Similar conformations were
observed for both the structures (RMSD ~ 0.6 Å) and they were also remarkably similar to the
activated opsin structures. When compared to the inverse agonist-bound receptor structure, the
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largest difference can be seen at the cytoplasmic surface where TM6 swings outwards by 11 Å or
14 Å. As seen in opsin structures, this outward movement is enabled by clockwise rotation of
TM6 at a helix turn preceding Pro6.50 due to interruption of its hydrogen bonding with the proline
residue, which is associated with repacking of Phe6.44. The ‘ionic lock’ is also broken, allowing
Arg3.50 to interact with the co-complexed Nb80 or GαS subunit. The unstructured ICL2 loop of
the inactive phase receptor forms a two-turn α-helix in the active phase receptor. An extension of
seven residues into the cytoplasm is observed for TM5 in the GS co-crystallized structure. The
quality of electron density for the cytoplasmic half is better than for the extracellular part,
indicating more variability of conformation in the ligand binding region, where only subtle
changes were observed. An inward bulge centered at Ser5.46 (a turn above Pro5.50) is seen, along
with slight inward movement of extracellular part of TM6 and TM7.
By employing the T4-lyzozyme fusion with14 or without15 thermostabilizing point
mutations, agonist bound adenosine A2A receptor structures have also been solved. The overall
architecture of the activated state receptor closely matches previously described activated
structures including a 2 Å bulge at TM5 (a turn above Pro5.50), distortions and a 2 Å shift along
TM3, inward movement of extracellular half of TM6 and TM7, and large scale displacement at
cytoplasmic ends of TM5, TM6 and TM7. However, TM6 is displaced by only 3-4 Å, where it
partially occludes the G protein binding site, which has led to suggestions that the observed
structures may represent an intermediate state.
An agonist bound crystal structure of M2 muscarinic receptor in complex with Nb9-8
camelid nanobody has also been reported with some departures from previously ascertained
‘active-like’ conformations. The extracellular half of TM5, TM6 and TM7 moves inward, while
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no movement or bulge is seen in TM3. Also unlike modest changes in orthosteric ligand-binding
sites of previously described receptors, a large scale inward movement of TMs closes the ligand
binding site and occludes the agonist from extracellular solvent. Incorporation of a positive
allosteric modulator in the crystal structure had no significant effect on the overall architecture of
the receptor.16
The receptor may couple with alternative interactions partners, the most commonly
studied being β-arrestin, which may result in different conformations for the receptor. The crystal
structures for 5-HT2B and 5-HT1B are available, and are very interesting primarily because of the
nature of the co-crystallized ligand, ergotamine.17 Ergotamine has a highly β-arrestin biased
function on 5-HT2B and less so on 5-HT1B. 5-HT1B-ergotamine complex shows active-state like
changes characteristic of activation via G proteins at the TM3 bulge, and TM6 rotation and
displacement along with a broken ionic salt bridge ‘lock’ between the DRY sequence of TM3
and the bottom of TM6. However, in the 5-HT2B-ergotamine complex, TM6 rotation is not
observed, but its TM7 movement and the location of the NPxxY sequence is more ‘active-like’
than in 5-HT1B. These observations have led to speculations demarcating conformational changes
in the receptor with functional selectivity of the ligand.

4.1.2 GPCR micro-switches
Micrco-switches are defined as a group of highly conserved residues having substantially
different conformations in active and inactive states of the GPCR such that alternate in
conformations of these residues help in stabilizing active, inactive or intermediate states of the
receptor.
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i) CWxP global toggle switch
This toggle switch was proposed to reconcile the apparent opposing movement of extracellular
and cytoplasmic regions of TM6 relative to the remainder of TM helical bundle. The tryptophan
residue at the position 6.48 was proposed to have ‘active’ and ‘inactive’ rotomeric states and the
presence of a conserved proline residue below the tryptophan would transduce the rotomeric
shift into a large cytoplasmic TM6 movement.18 However, no such ‘toggle’ mechanism has been
observed in crystal structures and mutagenesis studies have demonstrated activation of GPCRs in
the absence of the Trp6.48.19 However, due to its proximity to other highly conserved network of
residues it may play a physiologically relevant role in hydrophobic packing and disruption of
water networks.

ii) DRY motif
This highly conserved motif is present at the intracellular part of TM3, where Asp3.49 stabilizes
Arg3.50; Arg3.50 in turn forms a salt bridge with the acidic Glu/Asp at position 6.30, thus ‘locking’
the receptor in the inactive state (Figure 4.1A). While in the active state, the ionic lock is broken,
which allows displacement of TM6. Arg3.50 then interacts with ICL2 and the Gα protein.
However, this Glu is conserved in only 25% of class A GPCRs, and is not present in chemokine
and opioid receptors.20
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iii) NPxxY motif
Tyr7.53 of this TM7 motif moves toward the inter-helical bundle and forms a water network that
bridges its interactions with the Tyr5.58 residue in the active state (Figure 4.1B). This
displacement has been observed in all the crystallized ‘active’ state GPCRs.

	
  

	
  

Figure 4.1. A. DRY motif ‘ionic-lock’ in inactive state B. NPxxY motif rearrangement in
‘active-state’. Reprint from reference 8.
iv) P-I-F motif
This motif is composed of the clustered residues Pro5.50, Ile3.40 and Phe6.44. The TM3 bulge
observed in most active state receptor crystals is close to Pro5.50, causing the residue to move
slightly inwards. Concomitantly, the rotation of TM6 is correlated with a clockwise shift of
Phe6.44 (as viewed from the extracellular side), and its ‘inactive-state’ position is taken by an
alternate rotamer of Ile3.40. Interestingly, in the 5-HT2B–β arrestin biased ligand complex
structure, clockwise rotation of Phe6.44 is not observed, while it is seen in the 5-HT1B–unbiased
ligand complex structure where the characteristic placement of P-I-F motif is observed. (Figure
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4.2) This suggests that rotation of TM6 may be responsible for functional selectivity through G
protein recruitment.17

Figure 4.2. Movement in P-I-F motif in response to co-crystallization with ergotamine (dashed
red elliptical) B. Alignment between 5-HT1B (gray), inactive β2-AR (magenta) and active β2-AR
(yellow), 5-HT1B shows characteristic P-I-F movements seen in active form of β2-AR. C.
Alignment between 5-HT2B (green), inactive β2-AR (magenta) and active β2-AR (yellow), 5HT2B shows incomplete P-I-F movements in response to β-arrestin biased ligand (ergotamine).
Reprint from reference 17.

4.1.3 Bimodal and multimodal models for GPCR activation
GPCRs are now known to exhibit functional versatility owing to its interactions with G proteins,
β-arrestins, G protein receptor kinases (GRKs), and various other signaling proteins. This
functional versatility should be a product of structural plasticity. The GPCR population in a
given system can be described as an ensemble of discrete conformations whose energetics is
influenced by ligand binding, signaling and regulatory proteins, pH, membrane lipids, ions,
transmembrane voltage gradient and oligomerization. Under this model an ‘activation switch’
could be described as a shift in receptor sub-population in response to factors enumerated above,
and there could be more than one ‘activated’ state of GPCR, each of which is biased towards a
certain signaling profile.21
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Rhodopsin, so far a prototypical GPCR for agonism studies, may not fit into the above model.
Rhodopsin is unique in its high sensitivity and fidelity, and extremely fast ‘switching’ time. In its
inactive ‘dark’ state, the rhodopsin receptor is covalently bound to 11-cis retinal, which is a
highly efficient inverse agonist that ensures rhodopsin exhibits no basal activity. Isomerization of
11-cis retinal to the all trans form following photoactivation provides about 35 kcal/mol for
transition from bathorhosopsin to meta II rhodopsin22 through a series of extremely short-lived
intermediates. The meta II rhodopsin is capable of interacting with transducin within
milliseconds, and each rhodopsin can activate hundreds of transducins, which makes the receptor
system highly efficient.21 Moreover, all photoactivated rhodopsins proceed to the active meta II
form even in the absence of transducin, as evidenced by crystallization of the activated meta II
form without co-crystallization with transducin. Furthermore, the intermediates are too short
lived to interact with other proteins and have a signaling profile of their own. This supports a
‘bimodal’ model of GPCR activation for rhodopsin, where rhodopsin population can be
represented by two major discrete conformations and intermediate conformations are elaborate
switching mechanisms between the two major populations.
This ‘on-off’ model is in contrast to ‘multimodal’ model for other GPCRs that are known
to exhibit varying levels of basal activity, varying levels of ligand efficiency, interactions with
more than one kind of G protein, interactions with β arrestins and other G protein independent
signaling factors. β2-AR is one such example of a versatile but inefficient signaling machine.
Adrenaline binds with relatively low affinity with β2-AR in the absence of Gs (~ 1 µM) and each
binding event generates ~ 8.2 kcal/mol energy for activation.21 The ‘activated’ receptor crystal
structures of β2-AR could only be obtained in the presence of G protein or a G protein mimic.
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This suggests even agonist bound β2-AR has high conformational heterogeneity and only in
presence of another stabilizing factor (G protein) can somewhat homogenous ‘crystallizable’
populations be detected.
Figure 4.3 represents these two models. For rhodopsin, the inactive ‘dark’ state has the
lowest energy conformation, and photoactivation of the receptor increases the energy of the
‘dark’ conformation, resulting in conversion to the activated meta II state. In case of the β2-AR, a
heterogenous conformational population is observed due to the lesser difference between energy
states of different forms of the receptors. Agonist binding further reduces the difference and
stabilizes the ligand specific active form of the receptor, especially in the presence of G protein.
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Figure 4.3. Bimodal and multimodal GPCR activation models (a) Equilibrium between
rhodopsin, metarhodopsin II and metarhodopsin II-signalling complex. Energy profile of dark
state (dotted line), metarhodopsin II (green) and metarhodopsin II transducin complex (red). (b)
Equilibrium between, β2-AR and β2-AR-signalling complex. Energy profile of inactive β2-AR
(dotted line), agonist bound β2-AR (green) and agonist bound β2-AR- G protein complex (red).
Reprint from reference 21.
4.1.4 Unified GPCR activation model
The presence of highly conserved residues in seemingly varied GPCRs and identification of
constitutively active mutants have played a major role in generating hypotheses regarding the
GPCR activation mechanism. These hypotheses were further substantiated by various
biophysical studies. Furthermore, structural elucidations of active and inactive forms of receptors
have provided the ‘active’ and ‘inactive’ end points for the conformational spectrum of the
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receptors. Different researchers have interpreted questions regarding the sequence of events
leading to the activation ‘switch’ varyingly. Standfuss and co-workers, the group that crystallized
the active form of rhodopsin, proposed that rotation and movement of TM6 causes disruption of
water mediated interactions of Trp6.48 to Asp2.50, Asn7.49 and Ser7.45. This movement of Trp6.48
disrupts the hydrophobic barrier, enabling water present inside the helical region to form a
hydrogen bonding network between Tyr5.58 and Tyr7.53. Rasmussen and co-workers crystallized
the active form of β2-AR, and have proposed a different sequence of events. They contend that
ligand binding causes an inwards movement of TM5 in and around Pro5.50. This movement
disrupts the network of interactions between Pro5.50, Ile3.40, Phe6.44 (P-I-F motif) and Asn7.45. This
network disruption also causes rotation of TM6 around Phe6.44 and consequential outward
movement of TM6.
Tehan et al. have recently published a consensus mechanism based on superimposition of
active and inactive crystal structures identifying common movements - inward movement of
TM5, slight rotation and upward movement of TM3, rotation of TM6, and inward movement of
TM7 and TM1.23 The central thesis is that the activation is effected by rearrangement of
hydrophobic residues between TM3 and TM6 that hinders the water channel observed in active
states. The hydrophobic hindering groups consist primarily of Leu3.43, Phe6.44, X6.41 (hydrophobic
residue, Val for KOR). In the inactive state, the position of Leu3.43 is anchored to the top by
Phe6.44 and X6.41. Disruption of this network allows upward movement of TM3, rotation of TM6,
and inward movement of TM5. (Figure 4.4.A and B) Upward movement of TM3 also pushes
Leu3.43 towards Leu2.46 (Figure 4.4.C), whose inactive state position is now occupied by Asn7.49.
(Figure 4.4.D) Upward and inward movement of Asn7.49 allows Tyr7.53 to move across to the
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interhelical region where it forms hydrogen bond with Tyr5.53 through a water molecule. (Figure
4.4.E) These gross movements in TM3 and TM6 would break the ionic salt bridge, if present,
and opening of a water channel at the intracellular side stabilizes the resulting conformation.

Figure 4.4. Proposed GPCR activation mechanism. Red TM (inactive conformation); green TM
(active conformation). Inserts represent schematic overview of conformational changes in
highlighted helices. A. Rotational movement of Phe6.44 and upward movement of TM3 (Leu3.43).
B. Inward movement of Pro5.50 C. Displacement of Leu2.46 due upward movement in TM3. D.
Replacement of position previously occupied by Leu2.46 by Asn7.49. E. Movement of Tyr7.53 to
position previously occupied by TM6. Reprint from reference 23.
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4.1.5 Modeling active state receptor for KOR
Salvinorin A (Figure 4.5) is one of the most potent naturally (active constituent of plant Salvia
divinorum) occurring hallucinogens. Screening studies against an array of receptors, ion channels
and transporters, followed up by functional assays and mouse receptor knockout studies revealed
salvinorin A to be a selective KOR agonist.24,25 High binding efficiency of salvinorin A lends
itself for development of pharmacological tools and ligands with novel pharmacological profile
and therapeutic potential. In an effort to advance such exploration, irreversible agonists based on
salvinorin A skeleton were designed. Substituted-cysteine accessibility method (SCAM) studies
demonstrated the presence of free cysteine (not involved in a disulphide bond) in the solvent
accessible region.26 Modeling studies suggested the presence of Cys315 close to the putative
salvinorin A binding pocket26–28; furthermore, the 22-position on salvinorin A was identified for
inclusion of electron withdrawing groups to improve electrophilicity of this carbon, and such
ligands were synthesized. 22-thiocyanatosalvinorin A (RB–64) displayed high selectivity,
affinity and potency for KOR (Table 4.1) and a model for the RB64–KOR receptor complex was
proposed.29
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Figure 4.5. Salvinorin A (1) and RB-64 (22-thiocyanatosalvinorin A, 2)
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Table 4.1 Pharmacological profile of salvinorin A and its C-22 derivative RB-64.29
Compounds

Ki (nM)

Ki (nM)

EC50

Salvinorin A

1.8 ± 1.4

21 ± 11

17 ± 6

Relative Emax
(%)
100

RB-64

0.59 ± 0.21

39 ± 11

0.077 ± 0.016

95 ± 2

This chapter reports molecular dynamics (MD) experiments performed on the lipid bilayerembedded KOR-RB64 complex model. The obtained trajectory of KOR–RB64 complex was
then analyzed to determine a plausible KOR-agonist (RB–64) complex model and KOR protein
activation switch. Similar MD simulations were also performed on the recently crystallized
JDTic–KOR receptor complex30. These latter simulations were performed as a ‘control’ in MD
experiments.
Sodium is known to modulate GPCR receptor binding to G protein; inhibitory effects of
sodium to G protein binding have also been reported for opioid receptors.31 In the recently
crystallized high resolution structure of DOR, an allosteric sodium site was observed. KOR and
DOR share very high sequence similarity in the TM region, so an allosteric sodium site was
modelled on the KOR crystal structure, and similar MD simulation studies were performed.
Proteins show dynamic character at several scales – bond vibrations at femtosecond (fs)
timescales, side chain rotation at picosecond (ps) to nanosecond (ns) timescales, and large scale
domain motions at microsecond (µs) to millisecond (ms) timescale. The GPCR microswitches
involve movements of the side chains as well as larger scale TM movements such as
displacement and rotation. To achieve a higher degree of conformational sampling at nanosecond
levels an accelerated molecular dynamic approach was used.
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4.1.6 Accelerated molecular dynamics
Molecular dynamics is a widely used computational technique based on integration of Newton’s
equations of motion. It is fairly simple algorithmically and has the ability to accurately sample
the conformational space of a molecular system, thus allowing time-dependent behavior and
evolution studies. Accurate representation of a molecular system’s potential energy landscape
and the easily calculable thermodynamic and kinetic properties provide a special advantage
while studying local motion and conformational changes of proteins, DNA and other biological
systems. However, biological systems under study are usually large, hence simulation time has
traditionally been limited to around the nanosecond time scale.
As previously stated, a sufficient study of protein dynamics would usually require at least
milli- to microsecond time scales sampling to simulate large-scale conformational motions.
Moreover, for most biological systems, the energy landscape has multiple minima or potential
energy basins. These potential energy basins may have high free energy barriers. Dynamic
evolution from one basin to another would require sampling of series of rare events. A number of
MD methods have been introduced to approach this problem, such as conformational flooding,
replica exchange, umbrella sampling, hyperdynamics, metadynamics and the adaptive biasing
force method. However, they require prior knowledge of the potential energy landscape or
require an end point conformation.
Accelerated MD (aMD) has the advantage that it can simulate infrequent events without
any advance knowledge of the locations of either the potential energy barriers or potential energy
basins. The basic idea behind aMD is represented in Figure 4.6. In aMD, a threshold energy (E)
is defined, and at any time during the simulation if the true potential energy V(r) is below the
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threshold energy (E), a non-negative boost ΔV(r) is provided to the system so that there is a new
modified potential, V*(r) = V(r) + ΔV(r). The boost is defined by an acceleration factor α, where
small values for α represent faster acceleration.32

Figure 4.6. Schematic representation of the accelerated MD. Normal potential (black line),
biased potential (dashed lines).
V*(r) = V(r), V(r) ≥ E
V*(r) = V(r) + ΔV(r), V(r) < E
ΔV(r) = (E − V(r))2 / (α + E – V(r))
where, V*(r) = boosted potential
V(r) = actual potential
E = threshold energy
ΔV(r) = boost potential
α = acceleration potential
Generally, during conventional molecular dynamics simulations of biological systems, extensive
conformational sampling is done around a local minimum without adequately sampling other
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conformations. In contrast, the biased potential provides an increased escape rate from a local
minimum and subsequent evolution from one state to another occurs at an accelerated rate. This
provides highly enhanced sampling over a period of time and hence can be used to study protein
dynamics. The aMD method is reported to sample events with as little as 2000 times lesser
timescales than conventional MD (cMD)33 and is being increasingly implemented to study
biological systems.

4.2 Methods
4.2.1 Generation of receptor models
The RB-64-KOR complex model (KOR–Agonist model) was adopted from the model proposed
previously by Yan et al.29 Substituted–Cysteine Accessibility Method (SCAM) and molecular
modeling studies suggested Cys3157.38 to be the plausible site of irreversible binding to the KOR
protein. The model proposes covalent bonding of RB-64 to the thiol group of Cys3157.38 via a
disulfide bond. The preference for a disulfide linkage was demonstrated by mass spectrometric
studies following incubation of RB–64 with a synthetic peptide (Ac-YFCIALGY) to mimic the
covalent linkage between RB–64 and the KOR protein. Figure 4.7 represents the adopted model
demonstrating the site of RB–64 linkage on TM7 along with the crystallographic waters adapted
from KOR–JDTic crystal structure.30
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Figure 4.7. Cartoon representation of KOR demonstrating the point of linkage of RB-64 (sticks
representation) at TM7 through a disulfide bond. Crystallographic waters are shown as red
spheres.
The KOR–JDTic model (KOR-antagonist) was retrieved from PDB RCSB server (PDB ID:
4DJH)30. The receptor–antagonist model was prepared in Sybyl-X 2.0 by expunging all
substructures except for the KOR sequence, JDTic and crystallographic waters. Figure 4.8
represents placement of JDTic inside KOR protein as observed in the crystal structure.
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Figure 4.8. Placement of JDTic inside KOR as observed in the KOR crystal structure.

To explore the ‘sodium effect’ on KOR, the coordinates for sodium and the surrounding water
molecules were adapted from recently crystallized high resolution (1.8 Å) complex of human
DOR co-crystallized with naltrindole (PDB ID: 4EIY)34 following overlap with the KOR protein
substructure of KOR–JDTic crystal structure. A local minimization was done on amino acid side
chains at 10 Å radius from the sodium of the obtained KOR-sodium model (SybylX 2.0, 500
iterations, Gasteiger–Hückel charges, Tripos force field). Figure 4.9 represents the obtained
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sodium site model. Owing to the high sequence similarity between KOR and DOR, identical
interactions were observed.

Figure 4.9. Position of sodium inside KOR. Sodium (yellow), waters (red spheres), Side chains
of Asp105, Ser145, Asn141 and Asn322, and backbone chain of Leu101 (sticks) are shown.
By expunging all the substructures except the KOR protein and crystallographic waters from the
JDTic-KOR crystal structure, the apoprotein-KOR model was generated. Gaps in the protein
sequence due to removal of the T4-lyzozyme sequence and the non-resolution of ECL3 in the
crystal structure were modeled and refined using MODELLER 9v1035.
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4.2.2 Generation of topology and parameter files
Density functional theory (DFT) calculations at the 6-31G* level were employed to calculate
partial atomic charges of the JDTic and RB64–Cys315 atoms using NWChem 6.0.36 The
CHARMM force field parameter and topology files for the ligands (JDTic and RB-64) were
generated utilizing SwissParam.37 The atomic charges obtained from NWChem were added to
the ligand topology file. The default CHARMM topology and parameter files for proteins
(CHARMM22)38, lipids (CHARMM27)39 including CMAP40 corrections were further edited to
include topology and parameters for the ligands.

4.2.3 Generation of lipid embedded receptor complex
VMD 1.9.141 was used to prepare the system for MD simulations. Coordinate (pdb) and
connectivity (psf) files were generated for the receptor–ligand complexes as well as for the
apoprotein KOR and apoprotein KOR–sodium complex using the psfgen module. The VMD
membrane module was employed to create a lipid bilayer of POPC (1-Palmitoyl-2oleoylphosphatidylcholine). Coordinates for the spatial arrangement of the receptor within the
lipid bilayer were retrieved from the Orientations of Proteins in Membranes (OPM) database.42
OPM estimates arrangement of transmembrane protein inside the lipid bilayer by minimizing the
transfer energy of the protein from water to the lipid membrane. This was followed by the
addition of 30 Å of water in layers to both sides of membrane, using the VMD solvate plugin.
All the waters and POPC molecules at a distance of 0.65Å or less from the receptor–ligand
complex were then deleted followed by deletion of waters within the POPC membrane. The
water system was then ionized to 0.15 M of NaCl by the VMD autoionize plugin.
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4.2.4 Conventional molecular dynamics run
All molecular modeling simulations were performed using NAMD 2.8.43 The initial cMD
simulations were carried out in four stages, as described below:
i) Melting lipids
In the first stage, equilibration of the fluid-like lipid bilayer was performed via minimization
(1000 iterations) followed by NPT equilibration (pressure equilibration) of the lipid tails for a
period of 0.5 ns. Simulations were carried out under the CHARMM force field with
CHARMM22 parameters for protein, CHARMM27 parameters for lipids and CMAP corrections
for proline, glycine and alanine dipeptides and parameters for ligands (if present) with a timestep of 2 femtoseconds (fs). Periodic boundary conditions were employed, and Particle Mesh
Ewald (PME) summation was used to calculate long-range electrostatic interactions. Nonbonded interactions were calculated with a smooth cutoff between 10 to 12 Å with a frequency
of 1 fs. The constant pressure and temperature at 310 K was maintained via Langevin dynamics.
ii) Equilibration with constrained receptor–protein complex
In the second stage, an NPT equilibration of the system was run for a period of 1 ns with
harmonic constraints placed on the protein, the ligand (if present), the allosteric site sodium (if
present) and crystallographic water atoms (5 kcal/(mol-Å)), while keeping all the parameters the
same as earlier.
iii) Unrestrained equilibration of receptor–protein complex
The harmonic restraint was released in stage 3 and the entire system was equilibrated using the
NVT canonical ensemble for a further 1 ns.
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iv) Production run
The final production run was conducted using an NVT ensemble where the whole system was
simulated for 20 ns.

4.2.5 Accelerated molecular dynamics run
Accelerated MD simulations were also performed under NAMD 2.8.44 The dual boost method
was implemented for aMD, where boosts were provided for both potential energy and dihedral
energy. Threshold energy (E) and acceleration factor (α) were calculated by the following
formula:
a) Potential energy
Epotential = Vpotential_avg + 0.3 × Natoms
αpotential = 0.3 × Natoms
where Vpotential_avg = average potential energy for 20 ns of conventional MD and Natoms = total
atoms in the system

b) Dihedral energy
Edihedral = Vdihedral_avg + λ × Natoms,
αdihedral = (λ × Vdihedral_avg )/5
where Vdihedral_avg = average dihedral energy for 20 ns of conventional MD and Natoms = total
atoms in the system, λ = adjustable acceleration.
aMD simulations were run for all four systems under the same conditions as the production run
of conventional MD.
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4.3 Analysis
4.3.1 Stability of the accelerated system
The obtained trajectories for all four systems were examined for system stability. Long–term MD
simulations, particularly accelerated MD simulations, can result in disruption of secondary
structures such as helices. In lipid embedded systems, disorganization of lipid bilayers may
occur. To verify integrity of the system during the simulation, the final trajectory was checked
for quality of secondary structures (α-helicity) and stability of the POPC bilayer. (Table 4.2)

Table 4.2 Summary of Conventional MD (cMD) and Accelerated MD (aMD) simulations
System

α-helicity of
the crystal
structure
(%)

Length
of cMD
run (ns)

αhelicity
after
cMD
run (%)

Length
of aMD
run (ns)

KORJDTic

83.55(79.55)

αLipid
Surface
helicity
layer
area per
after
thickness
unit
aMD
after
lipid
run (%)
aMD
head P
run (Å)
(Å2)

20

83.58

70

73.72

50.73

22.43

KORRB64

20

79.70

80

74.73

55.26

23.46

ApoKORNa

20

82.81

60

78.94

50.40

22.87

Apo-KOR

20

81.00

80

82.32

51.50

23.06

The helicity of the secondary structure was calculated using STRIDE.45 The helicity measure of
the crystal structure is 83.55% or 79.55% (excluding and including unresolved amino acid
residues, respectively). 20 ns of the cMD run had no apparent effect on the helicity of the
protein. There was some decrease in helicity after the aMD run; however closer inspection of the
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trajectory revealed that unwinding of helix was confined to small regions. Furthermore, thickness
and density of the lipid bilayer remained fairly constant. This indicates that integrity of the
system was maintained through both conventional and accelerated MD runs.

4.3.2 Trajectory analysis
To simplify analysis of the trajectories, only the Cα atoms of KOR protein backbone were
mapped. These Cα trajectories were then fitted progressively (frame 2 onto frame 1, frame 3 onto
frame 2, etc.), to discount any translational or rotational motion of whole protein molecule
during the simulation. Principal components analyses were performed on the obtained Cα
coordinates.

4.3.2.a Analysis of KOR-JDTic lipid embedded complex (Receptor-Antagonist system)
Gromacs 4.4.3 utility tools were employed to analyze the obtained trajectories. Principal
component analysis (PCA) was performed using the g_covar utility. This utility calculates and
diagonalizes the covariance matrix to determine principal components describing the direction
(eigenvector) and associated amplitude (eigenvalue) of receptor (Cα atoms) motion. (Figure
4.10)
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.
Figure 4.10. Co-variance matrix for aMD trajectory of KOR-JDTic system. Both X and Y axis
define residue number (Cα atoms) Red color indicates positive covariance, blue denotes negative
covariance.
Figure 4.11 shows the eigenvalues for first ~33 principal components (PC) of ~800 components
calculated in PCA of KOR-JDTic system trajectory. The eigenvalues suggest that first two
principal components (PC1 and PC2) provide largest contribution to the covariance matrix and
hence can be used to represent overall fluctuations in the receptor trajectory.
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Figure 4.11. Eigenvalues (Y axis) associated with principal components (X axis) for KOR–
JDTic system

The ensemble of simulated conformations of the receptor (Cα atoms) was then projected twodimensionally (PC1 and PC2) by utilizing the g_anaeig tool. (Figure 4.12a) Red circles show
projections for the conformations simulated during the trajectory, while the projection for the
crystal structure is shown by a black triangle. This analysis reveals that a varied receptor
conformational space was explored during the simulation and the conformation for the crystal
structure was well within the conformational space sampled. Population analysis to detect more
probable conformations i.e. the conformations that were visited the most during the simulation,
was done using the g_sham module. (Figure 4.12b)
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The most
sampled
conformation

Figure 4.12. A. Projection of the receptor conformational space onto the two most significant
principal components. B. Sampling probabilities of the projection.
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The ‘heat map’ generated by g_sham module shows a spectrum of conformational occupancies
where the most highly sampled conformations are indicated by red and the least sampled
conformations are indicated by blue color. The most sampled conformations were found near the
projection for the antagonist bound crystal structure of KOR (black triangle in Figure 4.11A),
which suggests that the receptor is stabilized by JDTic (antagonist) in its inactive form. Root
mean squared deviation (RMSD) of the Cα atoms between a representative of the most sampled
occupancy (KOR–JDTic–rep) and the crystal structure was found to be 2.814 Å, Figure 4.13
shows the overlapped aligned helices for the crystal structure (red) and KOR–JDTic–rep
(yellow).

Figure 4.13. Overlaid and aligned conformations for crystal structure (red) and representative
structure of most sampled conformation during the simulation (RMSD = 2.814 Å)
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The alignment of KOR–JDTic–rep and KOR crystal structure showed limited deviations for Cα
atom positions and some changes in secondary structure, such as loss of the β-sheet in ECL2 and
the formation of 2-turn α-helix at ICL2. However, the overall architecture remained the same and
limited secondary structure variations have also been observed among the crystallized GPCRs,
particularly the presence of ICL2 α helix. Importantly, this analysis demonstrated that subjecting
the KOR–JDTic–lipid bilayer system to aMD maintained the integrity of the protein and highly
sampled conformations showed little deviation from the structure elucidated from KOR–JDTic
co-crystallization.
4.3.2.b Analysis of KOR–RB–64 lipid embedded complex (Receptor–Agonist system)
Similar procedures were also followed for analyzing the KOR–RB64 complex. Figure 4.14
shows the diagonalized co-variance matrix obtained from the Cα trajectory and Figure 4.15
shows eigenvalues associated with the principal components calculated for KOR–RB–64
complex simulations from the co-variance matrix.

Figure 4.14. Co-variance matrix for aMD trajectory of KOR–JDTic system. Both X and Y axis
define residue number (Cα atoms). Red color indicates positive covariance, blue denotes
negative covariance.
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Figure 4.15. Eigenvalues (Y axis) associated with principal components (X axis) for KOR-RB64
system.
The simulated trajectory was then projected based on the two principal components with the
highest contribution, PC1 and PC2. (Figure 4.16A) Red circles again denote the conformations
sampled during the simulation and the projection for KOR–JDTic crystal structure is indicated
by a black triangle. For this simulation, conformations with projections close to the crystal
structure projection were weakly sampled. The population analysis for the obtained projections
was done by probability sampling (refer to Figure 4.16B); as described earlier red denotes higher
occupancy for a conformation and blue indicates low occupancy. In this simulation, two major
distant clusters of high occupancy conformational projections were seen. The first three most
occupied projections were close to each other, while the fourth most occupied projection was
closer to the crystal structure projection. This suggested an apparent
152

	
  

4th most
sampled
conformation

The most
sampled
conformation

Figure 4.16. A. Projection of the receptor conformational space onto the two most significant
principal components. B. Sampling probabilities of the projection.
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transition in the receptor geometry projection were seen during early phase of the trajectory,
while the most occupied projection’s conformations start to appear around 58 ns (transition
time). The RMSD calculated between a representative conformation of the highest occupied
(KOR–RB64–rep-1) and the fourth highest occupied projections (KOR–RB64–rep-4), and the
KOR–JDTic crystal structure was 3.678 Å and 4.447 Å, respectively.

Figure 4.17. Overlaid and aligned conformations for crystal structure (red) and representative
structure of fourth most sampled conformation during the simulation (magenta), RMSD = 3.678
Å.
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Figure 4.17 shows the overlaid conformation for the fourth most sampled conformation and the
conformation observed in the crystal structure. KOR–RB64-rep-4 has a similar conformation to
that of the most populated conformation of KOR–JDTic system, except that β-sheet character of
ECL2 is maintained for KOR–RB64-rep-4. Since projections for both the conformation lie close
to the projection of the antagonist bound crystal structure, these conformations do not reflect
sufficient departure from the antagonist ‘inactive’ state of the receptor.

Figure 4.18. Overlaid and aligned conformations for crystal structure (red) and representative
structure of the most sampled conformation during the simulation (green), RMSD = 4.447 Å.
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Figure 4.18 shows the overlaid conformation of highest sampled conformation for KOR-RB64
system and the conformation of the KOR–JDTic crystal structure. Compared to the crystal
structure, significant variations were seen in KOR–RB64-rep-1 conformations. The inward
movement of TM6 at His6.52 (a turn above Pro6.50) driven by interactions with Asp3.32 is seen to
induce a sharp kink the helix, while both the top and the bottom of the helix move outwards. The
extracellular helix of TM7 unravels and the intracellular part of the TM7 moves inwards.
Outward movements were also seen in TM1 and TM2.

A complete protein trajectory study was undertaken (including both backbone and side chains)
for further analysis of conformational sampling of the simulation. Following parameters
associated with ‘active-like’ state of the receptor were analyzed:

a) Movements in P-I-F motif
As discussed previously characteristic conformational changes are observed at the P-I-F motif in
agonist bound GPCRs. Pro5.50 moves inwards, while the Phe6.44 side chain rotates towards TM5,
and the Ile3.40 side chain shifts to the position previously held by Phe6.44. As a result phenyl ring
of the Phe6.44 moves towards Pro5.50. This movement was analyzed by studying the evolution of
distances between the center of mass of Phe6.44 phenyl ring and the Pro5.50 backbone nitrogen.
(Figure 4.19) The distance between the two is ~ 8-10 Å in starting conformations, and remains
fairly constant through the simulation, especially in the most sampled conformation population.
Figure 4.20 shows the conformation state of the P-I-F motif in the representative of the most
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sampled conformation. No ‘active-like’ movements were observed for Pro5.50 (brown sticks),

Pro5.50-‐Phe6.44	
  
Distance	
  Å	
  
	
  	
  

Ile3.40 (green sticks) or Phe6.44.

Conformational frames
Figure 4.19. Evolution of distance between center of mass of phenyl ring of Phe6.44 and nitrogen
atom of Pro5.50. Each frame = 2 ps, red arrow indicates the ‘switch time’ (58 ns).

Figure 4.20. Conformational state of P-I-F motif in the highest sampled population in the
simulation. Phe6.44 (magenta), Pro5.50 (brown), Ile3.40 (green). Arrows indicate expected activestate like movements in respectively colored residues.
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b) Hydrogen bond network between Tyr5.58 and Tyr7.53
Another characteristic active state GPCR movement is inward movement of the cytoplasmic end
of TM7 towards the position vacated by outward movement of TM6. This inward movement of
TM7 brings Tyr7.53 close Tyr5.58, and the resulting hydrogen bond network through waters
stabilizes the active state of the receptor. The evolution of distances between the hydroxyl
oxygen of the tyrosines is shown in Figure 4.21. The distance between Tyr5.58 and Tyr7.53

Tyr7.53-‐Tyr5.58	
  
Distance	
  Å	
  
	
  	
  

increased during the simulation, instead of the expected decrease.

Conformational frames
Figure 4.21. Evolution of distance between hydroxyl oxygen atoms of Tyr5.58 and Pro7.53. Each
frame = 2 ps, red arrow indicates the ‘switch time’ (58 ns).
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Figure 4.22. Conformational state of Tyr7.53 and Tyr5.58 in the most highly sampled population in
the simulation.

c) Movement of cytoplasmic domain of TM6
Agonist–bound crystal structures show varying degrees of outward movements in TM6. It is
more pronounced in the presence of the G protein or a G protein mimic; however, limited
outward movement of the cytoplasmic domain of TM6 has been a constant feature in all agonistbound receptor crystal structures. Figure 4.23 depicts the evolution of distance between center of
mass of the protein and center of mass of the cytoplasmic domain of TM6. An outward
movement of ~ 2 Å is observed during the simulation.
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Conformational frames

Figure 4.23. Evolution of distance between center of mass of the receptor and center of mass of
cytoplasmic domain of TM6. Each frame = 2 ps, red arrow indicates the ‘switch time’ (58 ns).

Effectively, the major conformation observed, although different from the antagonist bound
crystal structure conformation, showed little evidence for the ‘active-like’ state. The most
prominent change observed in the receptor conformation was development of a sharp kink in
TM6 at the His6.52 residue. (Figure 4.24) This is possibly due to a salt bridge interaction between
carboxylate of the highly conserved Asp3.32 residue and the δN of the His6.52.
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Figure 4.24. Sharp kink in TM6 at His6.52, a half turn above Pro5.50 in KOR.

4.3.2.c Analysis of apoprotein KOR lipid embedded complex simulations
Analysis of the apo-KOR-allosteric sodium complex simulation demonstrates a constrained
conformation sampling compared to the conformations observed without allosteric sodium in
Apo-KOR. However, conformations with similar projections were sampled most often in both
cases. A plausible cause could be the loss of sodium from its allosteric site outside the
interhelical region, early in the simulation. The sampled conformations showed a sharp TM6
kink similar to those seen in RB-64 model.
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Figure 4.25. Eigenvalues (Y axis) associated with principal components (X axis) for Apo-KOR
system.

Figure 4.26. Eigenvalues (Y axis) associated with principal components (X axis) for Apo-KORallosteric sodium system.
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Figure 4.27. Projection of the receptor conformational space onto the two most significant
principal components. A. apo-KOR system B. apo-KOR-allosteric sodium system.

Figure 4.28. Sampling probabilities of the projections. A. apo-KOR system B. apo-KORallosteric sodium system.
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4.4 Discussion
Advancement in crystallographic techniques in the past decade has resulted in structure
elucidation of many GPCRs and the number of these structures is expected to grow. However,
each of these structures represents only one plausible conformation of the receptor under the
given experimental conditions, not least of which is the co-crystallized ligand. In fact, deviations
observed in receptor conformations while they are co-crystallized with ligands of different
functionality (agonism/antagonism/inverse agonism) are being employed to develop models for
receptor activation and functional selectivity.
This report describes an attempt to model the agonist bound KOR protein conformation
by utilizing the enhanced sampling capabilities of accelerated molecular dynamics. Four
different lipid embedded-water enveloped systems were built – KOR-agonist, KOR-antagonist,
apoprotein-KOR and apoprotein-KOR-allosteric sodium, and accelerated MD simulations were
carried out for > 60 ns after equilibrating via conventional molecular dynamics. All four systems
remained stable during the simulation and conformational sampling revealed major clusters of
similar conformations for each simulation. In the KOR–JDTic system (antagonist), the major
conformation was close to the crystallographic conformation observed for the protein in JDTic
co-crystallized KOR, indicating a fair reproducibility of experimental observations in the
simulation. For the KOR-RB-64 system (agonist), two major clusters of receptor conformation
populations were observed. Of these clusters, the minor population conformation was closer to
the conformations observed in antagonist-bound KOR, while the major population showed
divergence from the crystal structure conformations. However, analysis of the trajectory revealed
the absence of ‘signature’ active state conformational changes and the observed major
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conformational change was apparently effected by hydrogen bond interactions between His6.52
and Asp3.32.
The strong interactions between His6.52 and Asp3.32 resulted in a sharp kink in TM6 and
the unraveling of the extracellular domain of TM7 due to the strain in ECL3. Interestingly, B
factors for ECL3 are high for all three opioid receptor crystal structures and the ECL3 loop
remained unresolved in the KOR–JDTic crystal structure. His6.52 previously has been implicated
in opioid receptor agonist activation; mutagenesis studies have observed increased intrinsic
activity as well as conferring agonist-like actions to antagonists.46 Similar TM6 kinks were also
observed in apoprotein KOR simulations, these could reflect conformations responsible for basal
activity of the receptor.
Regardless, the observed TM6 kink could be an artifact of the simulation parameters. The
protonated imidazole form of histidine was used in the simulation, a choice that was based on
several test simulations that demonstrated the ability of protonated histidine to maintain the
surrounding water network as observed in the KOR crystal structure. However, this also ‘loaded’
the charged His6.52 with an additional hydrogen bond donor, which found a ready acceptor in
Asp3.32. An elementary remedy would be parameterizing non-protonated form of the histidine for
the simulation or to increase the simulation time period. Furthermore, the ionization state of the
solvent accessible histidine is likely to be in equilibrium, which may not be adequately
represented by either extreme.
The work detailed here presents an initial effort of building agonist phase models of the
kappa opioid receptor. Although the classical ‘active’ state conformation of the KOR receptor
was not achieved, the study does provides a good template for future studies. Notably, seemingly
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adequate conformational sampling was achieved within ~80 ns of accelerated molecular dynamic
simulation. Hence, optimization of the energy boosts for the accelerated simulation was realized
while maintaining the overall robustness of the system. The future studies require detailed
analysis of changes in the charged state of ionizable residues due to the structural changes in the
protein, particularly of the residues close to the ligand and to the allosteric sodium site.
Following successful building and validation of agonist–KOR complex models, corelational
conformation analysis of the residues can bring new insights into mechanism of GPCR activation
and functional selectivity of the ligands. Similar approaches can also be utilized to study other
opioid receptors as well as other GPCRs.
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CHAPTER 5
CONCLUSIONS

This report describes various strategies for protein structure-based drug design. In chapter 2, due
to the unavailability of the target protein (CCR5) structure, a homology modeling approach was
employed. The homology model of CCR5 was built based on the closely related CXCR4
template, following a rigorous sequence alignment including that of the secondary structural
features such as the disulfide bonds. The ligand binding site of the homology model and the
ligand docking scoring function were validated by examining the top scored docking solutions
with respect to the available site-directed mutagenesis data for binding affinities of known CCR5
antagonists. The docking modes of the lead compound (anibamine) were then proposed for the
validated binding pocket of the homology model. The exploration of anibamine docking modes
inside the receptor revealed weak interactions due to the high conformational flexibility of the
ligand inside the primarily hydrophobic and aromatic ligand binding pocket. In consideration of
the model, second generation anibamine compounds were designed with amine-linked aromatic
substitutions. Furthermore, water sites were generated inside the ligand binding pocket of the
CCR5 homology model. The superimposition of the generated water map on the docking modes
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of the previously docked ligands suggests entropy-driven binding of CCR5 antagonists due to
displacement of the conserved and highly ordered water molecules close to the crucial acidic
Glu283 residue. Some plausible hydrogen bonding interactions through the water bridges were
also observed. The results suggest the importance of including water molecules in receptorligand interaction studies.
In chapter 3, the selectivity profile of the naltrexone derived compounds was explored
with respect to the opioid receptors. The lead compounds, NAP and NAQ, were originally
designed on the basis of the identification of ‘address’ sites on the rhodopsin template homology
model of the opioid receptors. The results shown here validated the address sites of original
homology-based model and also proposed new address sites. The results indicate that the
naltrexone derivatives can interact with multiple address sites, depending on the position of the
substitutions attached, as well as the conformation a ligand may prefer inside the binding pocket.
In the MOR, two primary address sites were identified on the receptor for the 6substituted naltrexamine derivatives based on the docking experiments and sequence alignment
studies. The first site had aromatic as well as hydrogen bond donor moieties (Trp318 and
Lys303), which is a validation of the original homology based model. An alternate address site
was also identified, present close to the top of TM5 and ECL2. The second generation analogs of
NAP and NAQ were designed on the basis of the address sites identified here. However, loss in
relative selectivity of some of the second generation analogs was observed. Long term molecular
dynamic (MD) simulation experiments were performed with a representative of the second
generation analogs (NNQ) in complex with opioid receptors in a ‘plasma membrane-like’
environment. The results suggest that the ligand recognizes the address sites identified earlier in
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MOR; however, the functionalized moiety of the ligand interacts with the alternate regions in
KOR and DOR, which may compensate for lack of MOR ‘address’ site recognition. The nonbonded interaction energies calculated between the ligand and the opioid receptor validated the
compensation hypothesis.
The docking studies of 14-substituted ester-linked naltrexone derivatives on the opioid
receptor revealed another ‘address’ region in the MOR. This ‘address’ region was postulated due
to the variations in the conformation assumed by the conserved glutamate residue in the ligand
binding pocket following short term MD simulation experiments. In the MOR, the conserved
glutamate residue provided a hydrogen bond donor group to the 14-substituted naltrexone
derivatives because of its interactions with a non-conserved asparagine residue, present one turn
above. However, the conserved glutamate in KOR and DOR was ill directed for hydrogen
bonding, thus explaining the selectivity of the 14-substituted ester-linked naltrexone derivatives
towards MOR. However, this selectivity was lost for amine-linked derivatives, possibly because
of stronger conserved interactions between the amide linker and the conserved aspartate of TM3
in all three opioid receptors. Overall results suggest the presence of a good operational model for
understanding opioid selectivity for both 6- and 14-position substituted naltrexone derivatives.
Finally in chapter 4, structural insights from the recently crystallized ‘active-like’ GPCRs
were employed to identify ‘signature’ conformational changes that induce receptor activation.
Long-term accelerated MD simulation experiments were performed on the KOR-RB-64 (agonist)
complex in a lipid bilayer inside a water box. Distinct and highly populated receptor
conformations were achieved in the KOR-agonist simulation experiments that were significantly
different from the KOR-antagonist crystal structure conformation. However, these structures
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lacked the ‘signature’ conformational changes associated with receptor activation. The
protonation state of the crucial histidine in TM6 was identified as a plausible cause of
‘artifactual’ conformation. The study provides a template for future such experiments,
particularly the optimization of the energy acceleration such that significant conformational
sampling is achieved without damaging stability and integrity of the system. These studies are
promising for understanding receptor activation mechanism, the role of receptor residues and
motifs in ligand functions, functional selectivity of the ligand etc.
Overall, the studies reported here represent the evolution of molecular modeling
techniques with the advent of the GPCR crystal structures. For the majority of the past decade,
the receptor structure based computational studies were generally limited to homology modeling
approaches. However, with the advancement of crystallization techniques and the surge in the
number of available crystal structures, more comprehensive and extensive ligand-receptor
interaction and selectivity studies have come to fruition. Furthermore, the availability of activelike structures of GPCRs has opened a new paradigm of modeling ligand functions on the
receptor.
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